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BiomarkersTimely assessment of the aggregate health of small-area human populations is essential for guiding the opti-
mal investment of resources needed for preventing, avoiding, controlling, or mitigating exposure risks. Seek-
ing those interventions yielding the greatest beneﬁt with respect to allocation of resources is essential for
making progress toward community sustainability, promoting social justice, and maintaining or improving
health and well-being. More efﬁcient approaches are needed for revealing cause-effect linkages between en-
vironmental stressors and human health and for measuring overall aggregate health of small-area popula-
tions. A new concept is presented – community health assessment via Sewage Chemical Information
Mining (SCIM) – for quickly gauging overall, aggregate health status or trends for entire small-area popula-
tions. The approach – BioSCIM – would monitor raw sewage for speciﬁc biomarkers broadly associated with
human disease, stress, or health. A wealth of untapped chemical information resides in raw sewage, a portion
comprising human biomarkers of exposure and effects. BioSCIM holds potential for capitalizing on the pres-
ence of biomarkers in sewage for accomplishing any number of objectives. One of the many potential appli-
cations of BioSCIM could use various biomarkers of stress resulting from the collective excretion from all
individuals in a local population. A prototype example is presented using a class of biomarkers that measures
collective, systemic oxidative stress — the isoprostanes (prostaglandin-like free-radical catalyzed oxidation
products from certain polyunsaturated fatty acids). Sampling and analysis of raw sewage hold great potential
for quickly determining aggregate biomarker levels for entire communities. Presented are the basic principles
of BioSCIM, together with its anticipated limitations, challenges, and potential applications in assessing
community-wide health. Community health assessment via BioSCIM could allow rapid assessments and in-
tercomparisons of health status among distinct populations, revealing hidden or emerging trends or dispar-
ities and aiding in evaluating correlations (or hypotheses) between stressor exposures and disease.
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An efﬁcient, timely, and holistic approach for revealing cause–
effect linkages between environmental stressors and the health of
human populations persists as an unmet need. Presented here is
a new concept that targets biomarkers of endogenous human me-
tabolism that serve as measures of actual exposure and effects
from a wide spectrum of stressors extending beyond the traditional
focus limited strictly to chemicals. These biomarkers are normally
hidden in a uniquely rich source of chemical information that has
been largely ignored — raw (untreated) sewage. The concept –
termed BioSCIM (sewage chemical information mining targeted at
biomarkers) – could make possible the real-time collection of
exposure/effects data that reﬂects the overall, averaged health of
entire small-area communities.
Measures of community-wide health are rare. The only means of
assessment is currently limited to morbidity and mortality data and
conventional demographic data; included in morbidity data are spe-
ciﬁc sources such as poisonings and epidemiological studies (e.g.,
human biomonitoring). Morbidity data is not necessarily representa-
tive of an entire population (because of the incompleteness in report-
ing). It is also not possible to correlate any of these data with a
deﬁned population (or with stressors) in real-time.
Resource- and time-intensive epidemiological studies have been
the primary route by which speciﬁc cause–effect linkages can
sometimes be revealed. Indirect approaches, such as the CDC's Na-
tional Biomonitoring Program (CDC, 2010), establish body burdens
for a narrow spectrum of pre-selected xenobiotics in various body
tissues and ﬂuids (two examples being the analysis of biopsies for
PCBs or halogenated pesticides, or urine for phthalates). Biomoni-
toring for chemical stressors, however, only provides the means
for inferring the potential for exposure. Biomonitoring is unable to
address questions of linkage with human health effects. The body
burden of a chemical may simply be coincidental and of no biolog-
ical consequence. Although development of new approaches for
assessing human exposure is an ongoing task, most rely on ad-
vanced technology and are limited by the laborious requirements
and hurdles imposed by the need to test individuals (e.g., Borrell,
2011). They are simply not suitable for quickly assessing exposure
across entire populations.
A more direct approach for discovering potential linkages be-
tween environmental exposure and biological effects is the measure-
ment of endogenous biomarkers. In the context of human health,
biomarkers include physiological or behavioral responses, orendogenous biochemicals produced in response to: normal biological
processes (known as biomarkers of health), disease processes (as in-
duced by exposure to a biological, physical, radiological, psycho-
logical, or chemical stressor), or pharmacological intervention
(Biomarkers Deﬁnitions Working Group, 2001).
Conventionally, retrospective assessments (e.g., epidemiology;
biomonitoring) or prospective assessments (e.g., predictions based
on toxicology or in silico methods) have served as guides. But neither
of these approaches provides the ability to gauge collective,
population-wide health status or trends, nor can they provide mea-
surement in real-time. Consequently, they are not useful for support-
ing the use of short-term experiments (testing “what-if” scenarios)
or trial interventions that are essential for evaluating the outcomes
from actions intended to improve or maintain population-wide
health. Nor are they suitable for performing comparisons among
small-area populations — an especially important need for revealing
disparities regarding exposure or health between communities (e.g.,
environmental justice). In this sense, the BioSCIM concept presented
here can be viewed as a convenient means to facilitate or capitalize
on conducting so-called “natural experiments”. These quasi-
experiments are strictly observational, with non-randomized designs
that cannot be inﬂuenced by the researcher and which occur “as
is” in the course of ongoing events. Natural experiments are one
of the only approaches for evaluating the health outcomes from
community-wide interventions — whether targeted or not at in-
ﬂuencing public health. In this sense, they could play important
roles in public health research, especially for study of interventions
intended to reduce health inequalities (Petticrew et al., 2005).
Adding further complexity is the need to determine the compa-
rative impacts on health resulting from disparate classes or types of
stressors among the vast spectrum of possibilities (both anthropo-
genic and naturally occurring) to which humans are exposed. Cur-
rently not possible are meaningful assessments of the relative
importance of exposure to the continuum of chemical toxicants (sin-
gly or in combination; naturally occurring or anthropogenic), espe-
cially at the trace levels normally occurring in the ambient
environment. Even more insurmountable obstacles are faced in
assessing the relative importance among all stressors — prioritizing
across chemical, biological, physical, radiological, and psychological
(e.g., social or emotional) stressors. Further discussion of the back-
ground and rationale underlying the proposed BioSCIM concept is
presented in the Supplementary materials.
The proposed BioSCIM concept could serve as a key indicator in
the “Three Pillars” approach for sustainability, a rapidly evolving
18 C.G. Daughton / Science of the Total Environment 424 (2012) 16–38paradigm that must account not just for environmental factors, but
also social and economic factors in environmental decision making
(NRC, 2011). Since speciﬁc aspects of human health are impacted
by a conﬂuence of interlinked environmental, social, and economic
factors, BioSCIM indicators could serve as integrative measures for
sustainability. The application of BioSCIM to monitoring collective,
population-wide health holds potential for more effectively guiding
the development of sustainable communities and in reducing
inter-community disparities by facilitating the most effective inter-
ventions or corrective actions in greatly reduced time frames. This
ability is important in the Environmental Protection Agency's vision,
especially for measuring health disparities in vulnerable groups and
for demonstrating outcomes from numerous decision, compliance,
and enforcement activities (USEPA, 2010). A collective measure of
stress would hold the potential for making it possible for the ﬁrst
time to facilitate pinpointing which individual stressors play the
most important roles in community-wide disease — whether the
stress is chemical or non-chemical.
2. Biomarkers in sewage — BioSCIM
Proposed here is a concept for performing “remote” community-
wide biomonitoring — a means for monitoring the status or trends in
the collective health of small-area populations; the nature of small-
area populations and how their size can be measured has been pre-
sented (Daughton, 2012). The approach is highly innovative but also
conceptually simple — measuring biomarkers collectively excreted by
a community into sewage. If successful, it would provide for the ﬁrst
time the ability to derive a measure of population-wide health status
in a manner that has potential to be straightforward, fast, inexpensive,
widely applicable, amenable to automation, and scalable (applicable
to a broad spectrum of population sizes— ranging from local neighbor-
hoods to cities). Status or changes in community-wide health could be
quantiﬁed and then be used to seek correlations with community-
wide risk factors. Intra-community trends could be established, and
comparisons made across communities. A new paradigm could emerge
for justifying the prioritization of exposure risks and for determining the
optimal use of resources for control or minimization of exposure risks.
The potential advantages of the proposed approach include:
(i) acquisition of the data on exposure/effects-based biomarker
levels representative of entire populations in near real-time, (ii) elimi-
nating the need to obtain samples from individuals (a form of “remote”
monitoring), (iii) sufﬁcient time-series community-wide data could be
obtained for establishing status and trends, thereby making intra- and
inter-community comparisons possible, and (iv) the impacts of risk-
reduction actions could be more readily evaluated.
3. Generalized approach to developing a BioSCIM application
Development of a BioSCIM application begins with determining
the most promising biomarker to ﬁrst target in raw sewage. The com-
plete criteria are outlined in Table 1 and summarized in a ﬂow chart
(Fig. 1). The major attributes include whether the biomarker is: (i)
produced exclusively by disease or stress (i.e., not introduced by
unrelated, exogenous mechanisms), (ii) excreted in sufﬁcient quanti-
ties (to allow detection in sewage), (iii) sufﬁciently stable in sewage
(not degraded, such as by microbial activity), (iv) amenable to cost-
effective analysis in sewage while meeting whatever analytical
ﬁgures of merit are required, and (v) excreted at levels in stressed/
diseased states sufﬁciently elevated to discern signiﬁcant differences
compared with the narrow baseline range of “normal” basal states
(see Section 4: Reference intervals — “normal” versus stressed).
An appropriate monitoring method would include standardized
protocols for all steps beginning with sampling the raw sewage
and concluding with data reporting (see ﬂow chart, Fig. 1). Because
of the anticipated natural variance in biomarker basal (baseline)excretion (a function of both intra- and inter-individual natural
variations in excretion), coupled with the many irregularities associ-
ated with sewage ﬂow, it would be critical to minimize the analytical
variance to ensure that the signals are not obscured from any excur-
sions in biomarker levels resulting from perturbations due to critical
exposure events. A ﬁnal hurdle would be the need to ensure that
inter-laboratory variance is minimized — to eventually enable mean-
ingful intercomparisons between sewage treatment plants (STPs).
Importantly, the absolute accuracy of the analytical method
would not be critical — as long as the same standardized method is
used in all BioSCIM studies; analytical bias would only need to be re-
peatable. But precision would be essential. The absolute concentra-
tion of a biomarker in sewage has little meaning in terms of clinical
or epidemiological signiﬁcance – unless these levels could eventually
be used to reconstruct average systemic levels within the individual –
in a manner analogous to the use of FEUDS (Forensic Epidemiology
Using Drugs in Sewage) for reconstructing community-wide usage
of an illicit drug based upon the drug's concentration in sewage
(Daughton, 2011). In contrast, the reproducibility (and repeatable
bias) of the method is critical for distinguishing statistically signiﬁ-
cant changes in excreted biomarker levels.
The two major uses for BioSCIM both involve the inter-
comparability of per capita-normalized biomarker levels. These two
uses would entail intra- and inter-STP relative comparisons. Relative
values would rely on time-series data having sufﬁcient precision.
The value of relative levels is illustrated with an emerging approach
being implemented in a testing program for drug abuse in athletes. The
“Athlete Biological Passport” uses drug monitoring designed only to
detect changes (e.g., outliers) relative to the individual athlete's estab-
lished personal proﬁle of banned substances (those that are also en-
dogenous substances, such as certain anabolic steroids) (Sottas et al.,
2010). A major advantage in acquiring data for determining relative
changes is that the method of analysis need only be precise — yielding
reproducible values. Absolute accuracy is not important.
Intercomparisons would be used for establishing current status
and answering questions regarding trends (relative changes over
time): has a local per capita biomarker level changed over time?
What percentage increase or decrease in per capita level has a com-
munity experienced over time? Is a local level trending upward or
downward? How do the per capita levels or rates of change compare
between local communities?
A relativemeasure could reveal those communities with the highest
or lowest collective biomarker levels, or largest relative rate of increase,
and thereby guide subsequent studies to locate the risk factors. A
change in biomarker level could be viewed as analogous to a vehicle's
“check engine” fault light for a community at large — as an alert to a
possible increase in existing stress or emergence of new stress.
Signiﬁcant differences in inter-community comparisons could be
used in conjunction with data-rich geographic information systems
and demographic data to test for correlations with unlimited types
of geospatial variables — some obvious examples being noise (e.g.,
communities near airports, freeway interchanges, inner cities, green
spaces), population density, proximity to toxic chemicals (e.g., haz-
ardous waste sites) or other community disamenities (e.g., landﬁlls),
pesticide exposure (agricultural areas), radiation (high-voltage lines),
population age structure, respirable particulates (freeway trafﬁc or
regional air quality), and per capita income. In this sense, BioSCIM
would serve as a relatively quick screening tool that could then be
used to justify and guide more in-depth follow-up examination of
community-wide health as correlated with the presence or absence
of various exposure sources.
4. Reference intervals — “normal” versus stressed
Even if per capita basal levels of a biomarker for a particular STP
exhibited a sufﬁciently narrow range of variability at any point in
Table 1
Ideal attributes for biomarkers to target with BioSCIM.a
Biomarker attribute Example Potential limitation
Sensitive to changes in amplitude or
duration of stress, disease, or health
Excreted levels must be a function of the amplitude
of adverse or beneﬁcial health effect.
Some biomarkers can reﬂect both adverse and beneﬁcial
health effects.
Should be known what physiological
system or biochemical pathway the
biomarker acts upon or results from.
Range can span from very speciﬁc (a particular organ
or process) to systemic (whole body).
Biomarkers sometimes result from no endogenous process
but rather originate from exogenous sources (e.g., naturally
present in diet).
Must be excreted into sewage Excretion via urine rather than feces poses fewer
sampling and analytical challenges.
Excretion via feces creates a non-homogenous sample stream
and requires more comprehensive sample preparation.
Confounding of biomarker levels by
exogenous sources is minimal.
Low occurrence in raw or cooked foods
(or nutritional supplements), which are often
disposed directly into sewers.
Input possible from other animals where industrial/agricultural
sewage is mixed with human sewage (can confound data).
Confounding of biomarker levels by other
variables is minimal.
Levels can be perturbed by medications. Medications can up- or down-regulate biomarker biosynthesis.
Minimal intra-individual variance in
daily excretion.
Daily basal levels excreted by an individual vary
minimally over time (minimal diurnal or
seasonal ﬂuctuations).
Excessive variation will obscure ﬂuctuations due to changes
in health.
Minimal inter-individual variance in
daily excretion.
Per capita daily excretion across a population
varies minimally.
A wide spectrum of physiological variables can dictate the
excretion of biomarkers (age, gender, genetics).
Daily per capita excretion in sewage is
independent of extraneous variables not
considered risk factors.
Minimal effect from season, weather, geographic
locale, medications, water-use restrictions.
Genetic determinants can be a function of geography.
Occurrence levels in sewage independent of
design and usage of sewerage system.
Length of sewerage distribution pipes and residence
time of sewage in pipes.
Time-dependent degradation by microorganisms during
sewage transit can lead to variable reductions in biomarker levels.
Minimal degradation of biomarker in
ﬂowing sewage (levels persist in sewage).
Slow degradation allows sampling raw sewage
further downstream, permitting better mixing of
inﬂuent “pulses”; ensures minimal loses during
transit through sewer
connections of varied lengths and residence times.
Sewage pulses with widely varying biomarker levels (compounded
by changing pulse frequency) greatly increase the required
frequency of sampling.b
Levels in raw sewage are well above
method detection limits (MDL).
Few analytical interferences; easier implementation
of a routine method.
Isobaric biomarker isomers often become common interferences;
this is particularly problematic, for example, with isoprostanes;
many potential biomarkers with potent physiological action are
not useful since they are excreted at extremely low levels.
Minimal potential for exogenous
interference from other sources.
Exogenous sources include residues of target
analyte on analyst's hands.
Residues of target analytesb can sometimes be excreted in sweat.c
Homogenous distribution; biomarker
preferably partitions to aqueous phase.
Minimal partitioning to dissolved or suspended
solids or sludge.
Partitioning to solids increases the complexity of sampling and
sample preparation; this occurs especially when a biomarker is
excreted via the feces.
Minimal degradation of biomarker in
sampled sewage (levels persist in
stored sewage samples).
Refractory to microbial degradation or to further
physicochemical degradation during sample
shipment or storage.
Preservatives may be required to inhibit microbial degradation
in stored or shipped samples.
Minimal de novo, ex vivo formation
of analyte in sewage.
Minimal formation by microbial activity during
sewage transit and during sewage treatment.
Sampling of raw sewage as early as possible in inﬂuent stream
may be necessary.
Minimal sample clean-up and
sample preparation
Requires minimal pre-concentration to meet MDL. Excretion of biomarker in the form of conjugates may require
time-consuming hydrolysis step.
Analytical determination uses
instrumentation routinely available;
analytical methodology amenable
to standardization.
Conventional GS/MS, LC/MS, or immunoassay Innovative “research grade” methodologies are too costly or
complex for wide implementation.
Minimal capital investment in
instrumentation; minimal analyst time.
Allows for high-frequency sampling “Research grade” methodologies are too costly for wide
implementation.
Amenable to high sample through-put Amenable to automation; reduces cost Analyst intervention reduces timeliness of results
Potential for in-stream continuous sampling
or monitoring
Equilibrium passive samplers (EPS) allow for
passive, time-integrated sampling;d in-stream
sensors facilitate real-time data.
Discrete sampling gives biased results because of stream
heterogeneity and sewage pulses.
Minimal occupational hazards for
technicians
Minimal hazards from samples, and from
analytical reagents or reactions.
Handling raw sewage poses risks associated with
pathogen exposure.
a Adapted in part from Daughton (2012).
b The challenges associated with obtaining representative samples from an STP are discussed by Ort et al. (2010).
c Daughton and Ruhoy (2009).
d Examples of EPS (Zabiegała et al., 2010) include polar organic chemical integrative samplers (POCIS) and semipermeable membrane devices (SPMD).
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– a major question is whether it would be possible to assign the com-
munity an absolute measure of “health” or “stress”. To answer the
question of whether a local per capita biomarker level is “abnormal”
is considerably more difﬁcult.
Fundamental questions surround what is even meant by “normal”
(or “healthy”) versus “diseased” — or “non-diseased” versus “non-
healthy”. For the purposes of BioSCIM, it would require a comprehen-
sive series of initial monitoring studies across carefully selected STPs —
those serving populations with well-documented overall health. These
studies would be needed to establish “normal” ranges (baseline physi-
ological levels for a population deemed to be “healthy”) for thetargeted biomarker. Data from individual sewage treatment plants
(STPs) would serve instead of the data from individual human subjects.
Entire communities would be viewed as individual patients (Daughton,
2012).
These studies would be analogous to the clinical studies required
for establishing the widely used reference intervals or reference values
for blood or urinary levels of various markers — a concept introduced
in 1969 by Gräsbeck (2004). A uniﬁed approach for conceptualizing,
deﬁning, and developing reference values was begun in 1970 and
summarized in a series of papers beginning in 1987 (Solberg, 1987).
Despite the widely accepted and routine use of reference intervals
in clinical chemistry for a wide spectrum of biochemical parameters,
minimal:
> intra- & inter-individual variance in temporal excretion
     from endogenous production
> influence of circadian rhythm
> genetic* influences: gender; metabolism; ethnicity
> environmental* influences: age; diet; weather & season
> excretion as metabolic conjugates
     *genetic and environmental variables can be closely
      linked, especially via epigenetics
> cost minimized by use of standardized methods
     using widely accessible laboratory instrumentation
> minimal analytical variance
> amenable to automation
> amenable to in-stream detection via sensors
> stability: minimal susceptibility to microbial transformation,
     physicochemical alteration, and sorptive removal;
     ideally, refractory to chlorination
> excreted conjugates naturally hydrolyzed in sewage
> minimal de novo formation (e.g., via microbial synthesis)
minimal exogenous contributions from:
> undigested food
> cooked & raw food disposed into sewers
entry to sanitary sewerage
via human excretion
(urine & feces)
transport via sewer
ease of analysis
in sewage
> levels normalized to population serviced by STP or to a
     biomarker whose per capita excreted levels have low
     variance (e.g., coprostanol)
> alternatively, calculate index of relative levels with ratio of
     biomarkers whose levels move in opposing directions
     (e.g., biomarker of disease or stress versus biomarker of health)
reporting community-wide trends
or inter-community comparisons
biomarker of
disease or health
7.3
6.35
300.
240.
180.
120.
60.
.66
14.62
10.6
min
R
el
 R
es
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ns
e
13.6 17.2 20.5
Fig. 1. Characteristics of an ideal biomarker for BioSCIM.
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with numerous challenges and far exceeds the scope of this paper.
Comprehensive examination of the complexities, limitations,
and pitfalls surrounding the development of reference intervals
for laboratory medicine, which necessarily must accommodate
natural biological variability, is available from a number of authors,
including Apostoli et al. (1998), Gräsbeck (2004), Henny and
Petersen (2004), Hyltoft-Petersen and Henny (2004).
The idea of examining an entire local community as if it were an
individual patient poses many additional challenges than already
encountered in establishing clinical reference values for inter-
individual comparison. At the least, however, it should be possible
for a local community to serve as its own reference (analogous to
the clinical practice of “delta checking” based on intra-individual
time-series reference values, or the Athlete Biological Passportmentioned above) if the contribution to intra-community variance
(i.e., combined inter- and intra-individual variations for “healthy”
individuals — due to both analytical variance and natural daily var-
iation) — is sufﬁciently small. A reference range for BioSCIM would
at least only need the power to differentiate between a positive or
negative relative change in status.
Regardless of whether it is possible to establish reference values
(and intervals) for BioSCIM analytes, it would be possible to establish
ranges based on (for example) the upper quintile (or lower quintile
depending on whether the desired relative level of the selected bio-
marker should be high or low) of community-wide values. Values
from a given STP could then be expressed relative to the extreme
range, which could be termed the “target range” or some such —
a range that a community might strive to reach by implementing
appropriate measures to improve health or avoid stress.
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Sewage can be viewed as “chemical litter” emanating from human
behavior, actions, and activities. It has long been regarded as econom-
ically burdensome waste— only recently viewed as a potential source
of nutrients for agriculture or for reclaiming energy (e.g., Heidrich
et al., 2010).
BioSCIM makes use of the wealth of chemical information pre-
sent in sewage and relevant to health and disease. This rich but
highly complex reservoir of potential biomarkers has never been
mined. It resides in raw sewage in the form of unique signatures
from countless chemicals excreted from the body as a result of myr-
iad endogenous biochemical processes. In raw sewage, these sub-
stances represent the combined metabolic processes from all
individuals composing a small-area population serviced by a dis-
crete STP at any point in time. Applications of SCIM essentially
serve as a form of community-wide, en mass urinalysis — where sin-
gle samples (collected over sufﬁcient time) are necessarily repre-
sentative of the entire population. The potential application of
SCIM is ﬂexible in terms of selecting well-deﬁned small-area popu-
lations. The physical layout of sewer conveyance lines enables the
collection of samples from different spatial locations, representing
different segments of a population — spanning discrete hierarchical
subgroups ranging from portions of a city, community, neighbor-
hood, or particular street.
One way to apply BioSCIM in quantitative assessments necessi-
tates knowing the size of the real-time population contributing to
the sewage. This allows calculation of average per capita contribu-
tions (or loadings) of a biomarker. There are many limitations and
complexities surrounding the concept of a small-area population.
Their ramiﬁcations with respect to SCIM are discussed in Daughton
(2012), as an application termed ASAP-SCIM (analysis of small-area
populations by sewage chemical-information mining), which pre-
sents a new concept for estimating small-area population size by
use of biomarkers whose constant levels of excretion reﬂect per
capita contributions. An alternative approach for BioSCIM would ob-
viate the need to directly know the population size. This could be
done by monitoring for an orthogonal biomarker (such as a biomark-
er of health rather than stress) whose level the target biomarker level
could be normalized against. This would create a dimensionless or
normalized index (discussed in Section 11: Differential Stress Index:
increasing the sensitivity of BioSCIM by also measuring biomarkers
of health to derive a normalized index of stress or homeostasis).
The BioSCIM approach could also be viewed as a form of remotely
sensed, collective HBM, where no active involvement or participation
from any individual is needed. Although BioSCIM's economy of scale
cannot generate data relevant to the individual, it generates time-
series data and would facilitate quick inter-community comparisons.
BioSCIM holds the potential for minimizing or eliminating the issues
and concerns normally surrounding subject recruitment, retention
and participation of recruits (“research fatigue”), informed consent,
and conﬁdentiality — all of which are problematic for HBM studies
and often even for epidemiology (Bauer, 2008). The non-invasive na-
ture of BioSCIM would negate the need for recruiting and interacting
with individual subjects and thereby obviate any requirement for In-
stitutional Review Board approvals. This could greatly accelerate the
pace of studies.
The NRC (2009) has noted the need for simpler screening-level
tools for assessing cumulative risk — especially at the community-
wide scale. BioSCIM would serve as a ﬁrst attempt at providing such
a tool based on a biomarker of effect. As recommended by the NRC,
the new concept might also facilitate the conduct of risk assessments
by community stakeholders, thereby empowering more involvement
in evaluation, design, and management of local remedial or control
activities. Access to near real-time data could facilitate the testing of
what-if scenarios — one example of many being encouraging changein community-wide behaviors and evaluating possible subsequent
changes in BioSCIM biomarker levels. BioSCIM could create the op-
portunity to view communities from a completely new perspective —
where an entire community serves as the patient (Daughton and
Ruhoy, 2011).
In addition to developing the framework for the BioSCIM remote
biomonitoring concept, initial proof of principle is currently being
planned by development of an analytical methodology for measure-
ment of an effects-based biomarker in sewage. This may mark the
ﬁrst time that an effects biomarker has been targeted in the monitor-
ing of sewage. Theoretically, comprehensive arrays of biomarkers
suitable for monitoring in sewage could eventually be developed.
Chemical information can be derived from the full spectrum of chemi-
cals excreted by humans (including those in urine, feces, and sweat).
These markers could range from general to speciﬁc in terms of the
types and levels of biological effects they indicate.
5.1. Evolution of the SCIM concept: from FEUDS and ASAP-SCIM
to BioSCIM
The BioSCIM concept derives from prior work directed at the ex-
traction of chemical information from sewage. The proposed BioSCIM
concept represents a new application of a general approach called
sewage chemical-information mining – SCIM (Daughton, 2012) –
speciﬁcally targeted at select biomarkers. The real-time monitoring
of sewage for biomarkers as measures of community-wide health
and disease was ﬁrst proposed by Daughton (2011) and shortly
thereafter by Thomas and Reid (2011); it has also been mentioned
by Fanelli (2011). The work reported here resulted from a U.S. Envi-
ronmental Protection Agency (EPA) 2010 research proposal on SCIM
funded by EPA's ORD Pathﬁnder Innovation Projects (PIP) internal
grants program (Daughton, 2010).
The ﬁrst application of SCIM for extracting information from
community-wide contribution of chemicals to sewage was intro-
duced in 2001 (Daughton, 2001) and was ﬁrst applied to real-world
use in 2005 (Zuccato et al., 2008). This original concept (sometimes
loosely referred to as “sewer epidemiology” or “sewage epidemiolo-
gy”) involved analysis of domestic sewage for illicit drugs (or their
metabolites) and using pharmacokinetics and sewage ﬂow rates to
back-calculate aggregate and per-capita drug usage for an entire com-
munity served by the STP. This application represented the ﬁrst time
that aggregate dose-reconstruction could be accomplished at such a
large scale. This application of SCIM has since been widely explored
internationally. It was later termed Forensic Epidemiology Using
Drugs in Sewage (FEUDS); for a review see Daughton (2011).
A second application of SCIM was introduced in 2011 and termed
ASAP-SCIM: Analysis of Small-area Populations by Sewage Chemical-
Information Mining (Daughton, 2012). This approach was proposed
as a means of providing near-real-time estimates of small-area
(local) populations by measuring select biomarkers excreted into
sewage. ASAP-SCIM may prove useful in the implementation of BioS-
CIM. BioSCIM represents the third methodology based on SCIM and
strives to monitor for biomarkers in sewage as a gauge of
community-wide health. It is worth noting that most of the complex-
ities associated with the actual implementation of FEUDS and ASAP-
SCIM also apply to BioSCIM. So understanding the ﬁrst two applica-
tions helps with understanding the limitations and challenges faced
by BioSCIM.
Important to appreciate is the complexity surrounding the estima-
tion of small-area population size in interpreting population-wide
measures of health. When the small-area population (or change in
population) is not accurately known, then the signiﬁcance of absolute
changes in health measures (mortality being one of the simplest ex-
amples) cannot be evaluated (Daughton, 2012). Any change in inci-
dence can result from changes in any or all of three factors
(Thunhurst, 2009): (i) absolute population (constant rate of
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(ii) composition of constant population (changes in disaggregation,
resulting in higher percentage of vulnerable individuals— an example
being an inverted age structure), or (iii) response of the overall
population (e.g., changes in stressor levels). A methodology for easily
resolving these factors is currently not possible.
A noteworthy aspect of the proposed BioSCIM approach is that it
could theoretically also be extended for use in ecological assessments,
especially given the emerging ﬁeld of “oxidative stress ecology”
(Costantini et al., 2010). It might prove particularly applicable, for ex-
ample, in determining the health status of local aquatic environments—
by measuring select biomarkers excreted by aquatic organisms in their
native environment; biomarkers of oxidative stress (already used in
assessing individual organisms) constitute one example that may
prove useful (Isaksson, 2010; Lushchak, 2011; McGraw et al., 2010;
Metcalfe and Alonso-Alvarez, 2010).
6. Biomarkers
Perhaps some of the most important information contained in
sewage is represented by the countless excreted substances serving
as biomarkers— substances having potential as measures of collective
community-wide disease, stress, or health. Biomarkers comprise
three major categories in terms of what they can indicate (Hagger
et al., 2006): exposure (e.g., as measured by dose), effects (e.g., diag-
nostic indicators, especially toxicity or other biological endpoint such
as pathogenicity, or alteration of structure/function), and susceptibil-
ity or vulnerability (e.g., prognostic indicators, such as genetic poly-
morphisms); a summary of the requirements for biomarkers is
presented in Breusing and Grune (2010). Biomarkers can therefore
serve as diagnostic or prognostic measures of exposure, stress, vul-
nerability to disease, emerging disease, overt disease, or health. Bio-
markers include endogenous biochemicals produced in response to
stress or indicative of health. They also include adducts of xenobiotics
or endogenous chemicals. And of course, they include metabolites of
detoxication or intoxication processes resulting from xenobiotic ex-
posure. Analysis of sewage for biomarkers, as a collective measure
of population-wide health status or stress, has never been reported.
Such an application would be aligned with the ﬁeld of “molecular
epidemiology” (Bonassi and Au, 2002), especially since a carefully
selected biomarker can serve to integrate a diverse array of expo-
sures — regardless of type, source, or route.
Biomarkers are often used as proxy or surrogate measures of the
actual biological process of interest (for example, a toxicological or
disease endpoint or outcome) but which is too difﬁcult to directly
measure itself. Chemical and biochemical biomarkers are generally
measured in tissues (including hair and nails) or body ﬂuids. The
ﬁdelity with which biomarkers mirror the endpoints of interest varies
widely. Well-known examples include the measurement of mercury
(or other metals) or drugs in hair or nails (as an indicator of whole-
body exposure) and blood pressure and serum cholesterol (as indica-
tors of vulnerability to heart disease). Some biomarkers are prognostic—
indicators of the potential for developing disease, or even disease that
has yet to manifest with outward signs. For health conditions with link-
ages to the environment, prognostic biomarkers and vulnerability bio-
markers could be used to guide the design of remedial actions in the
immediate environment to prevent or lessen the probable onset or wors-
ening of pathologies. The utility of biomarkers is not just in diagnosis, but
also in guiding the selection of subsequent assessment studies for mea-
suring the effectiveness and progress of interventions or other remedial
action.
Major limitations in the conventional measurement of any bio-
marker are the demands on clinical and laboratory resources and
the time required for obtaining samples from statistically sufﬁcient
numbers of individuals in order to extrapolate conclusions to entire
communities or populations; additional hurdles are in gaininghuman-subject testing approvals. Historically, biomarkers clearly
have a number of major limitations in studies at the higher levels of
populations or communities for establishing (at a minimum) expo-
sure proﬁles.
The characteristics of useful biomarkers, partly adapted from
Hagger et al. (2006), include those summarized in Table 1. The sew-
age matrix adds considerable complexities to nearly all of these.
Each of these factors and others would eventually need to be ex-
amined before a suitable biomarker (or suite of biomarkers) is select-
ed for measuring community-wide stress using BioSCIM. These are
summarized in Table 1. These factors place additional restrictions on
the utility of a biomarker, further narrowing an already rather re-
stricted ﬁeld of possibilities. The numbers of bona-ﬁde biomarkers —
those with accepted clinical utility — are extremely limited to begin
with. Despite the ever-expanding published literature on biomarkers
(many resulting from the various ﬁelds of omics), the number of bio-
markers that have been validated for use in routine clinical practice
may be fewer than 100 (Poste, 2011).
A comprehensive examination of the ﬁdelity with which bio-
markers actually measure disease is presented by Ioannidis and
Panagiotou (2011); also see Bossuyt (2011). This study revealed
major shortcomings in the purported utility of a range of select bio-
markers (for roughly two dozen risk factors) for use in diagnosis,
assessing vulnerability, establishing prognosis, or guiding treatment.
The markers examined were all proteins, genes, or chemicals such
as estradiol (which have multiple origins). None of the markers, how-
ever, included a biomarker that was amenable to measurement in
sewage or that reﬂected general modes of disease development,
such as inﬂammation (with the possible exception of C-reactive pro-
tein: CRP). One controversy surrounding the demonstration of bio-
marker ﬁdelity with disease is whether large, controlled clinical
studies are required (Bacchetti et al., 2011).
7. Effects biomarkers suitable for BioSCIM
In the course of this work, over 900 publications were examined
for their possible relevance to different aspects of BioSCIM and to
extract supporting data. These articles resided primarily in the ﬁelds
of clinical research, analytical biochemistry, lipid chemistry, exercise
physiology, nutrition, toxicology, and free radical research. One of
the primary objectives was to identify the best candidate biomarker
with which to develop the initial BioSCIM application. Possible can-
didates were evaluated on the basis of the criteria in Table 1. The
other objective was to use this candidate biomarker to highlight
the types of information and data needed to assess biomarkers in
general for use with BioSCIM.
7.1. The Isoprostanes (IsoPs) — biomarkers of systemic, system-wide
oxidative stress
After evaluating a range of biomarkers as candidates for BioSCIM,
the biomarker selected to demonstrate proof of principle belongs to
the class of prostaglandin-like isomers — the isoprostanes. The iso-
prostanes (herein referred to generically as IsoPs) were ﬁrst proposed
for use as a measure of oxidative stress in 1991 (Morrow and Roberts,
1991) and have since been accepted in clinical chemistry as the
biomarkers that provide the best quantitative measure of total sys-
temic oxidative stress, which serves as a general pathway toward cel-
lular dysfunction (Milne et al., 2008). The biosynthesis of IsoPs was
ﬁrst delineated in 1990, but this new series of prostaglandin-like iso-
mers was not named isoprostanes until 1992 (Morrow et al., 1990a,
1990b, 1992).
The IsoPs gained recognition as the most reliable, sensitive, and
speciﬁc non-invasive measure of in vivo, systemic oxidative stress
after a comprehensive series of studies in the early 1990s using rats
that were administered carbon tetrachloride. These studies
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comparative assessment of a spectrum of candidate biomarkers of ox-
idative stress — the Biomarkers of Oxidative Stress Study (BOSS) of
the National Institute of Environmental Health Sciences (Milne and
Morrow, 2006). Somewhat analogous studies have since been done
with human subjects (Il'yasova et al., 2010).
While the term “oxidative stress” is not rigorously deﬁned, it gen-
erally refers to an imbalance in the levels of reactive oxygen, nitrogen,
and halogen species relative to the body's defense mechanisms – a
perturbation in the prooxidant–antioxidant balance resulting in dis-
ruption of redox signaling and control – more recently termed
“redox disruption” (Breusing and Grune, 2010; Burgos Alves et al.,
2010; de Castro Fernandes et al., 2010; Jones, 2006, 2008); reactive
species include both free radical and non-radical oxidants. Indeed,
the prevalence of redox disruption versus free-radical oxidation
may explain the lack of expected effectiveness of antioxidants
reported in many clinical studies.
Oxidative stress originally attracted attention because of the key
role it was theorized to play in aging; this theory was an extension
of the original “free radical theory” of aging, proposed and advanced
in the 1950s by Harmon (see: Kregel and Zhang, 2007). The history
of oxidative stress in disease and in maintenance of homeostasis via
cellular signal transduction is provided by Hensley and Floyd (2002).
Regardless of its deﬁnition, oxidative stress is widely viewed as a
hallmark of various acute and chronic diseases, many of which are
also part of the normal aging process (Montuschi et al., 2007). Oxida-
tive stress has become recognized as a central factor is the prevalence
of chronic inﬂammatory diseases, including obesity, hypertension,
cardiovascular diseases, and type 2 diabetes, among others that de-
ﬁne the metabolic syndrome (Jesmin et al., 2010); for all but three
of the 15 leading causes of death in the US (Kochanek et al., 2011), in-
ﬂammatory pathways (including those involving the production of
IsoPs) play roles. Note, however, that oxidative stress in itself is not
necessarily deleterious, but rather can sometimes be viewed asCASR
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Fig. 2. Example of a common isoprostane (and a prostaglandin isomer), togethhealthy or necessary — “eustress”; IsoPs may play roles in governing
cellular adaptive response to stress via gene expression and cell signal
transduction (Niki, 2008; Noguchi, 2008). A certain controlled, back-
ground level of oxidative stress probably plays critical roles in adap-
tive physiological responses and in critical biological defensive
functions (Azzi, 2007). The state of what is known regarding the cor-
relation of oxidative stress and disease has been reviewed by
Giustarini et al. (2009).
Although IsoPs are isomers of prostaglandins, they are not directly
related, as their mechanisms of in vivo synthesis and their biological
functions differ dramatically. The prostaglandins are produced direct-
ly in free form by a complex cascade of enzymatically catalyzed reac-
tions (via COX — cyclooxygenases) beginning with free arachidonic
acid (see Fig. 2) — or any fatty acid with at least three double
bonds, notably the essential fatty acids, eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA). In contrast, the IsoPs are predomi-
nantly formed from the non-enzymatic, free-radical peroxidation and
cyclization of these same fatty acids only after they have been esteri-
ﬁed to cellular membrane phospholipids (at the sn-2 position); note
that “peroxidation” generally refers to reactions involving di-
oxygenation but some oxidative reactions of lipids involve mono-
oxygenation. Oxidation is initiated on the bis-allylic methylene
groups (saturated carbon adjacent to two-double-bonded carbons in
the cis conformation) of the polyunsaturated fatty acid. This non-
speciﬁc autooxidation results in numerous isomers — and therefore
a complex and often confusing nomenclature.
Structurally, the prostaglandins and IsoPs differ only by conforma-
tion (stereochemistry). Each of the three major classes of IsoPs (F-, D-
and E-series) can theoretically comprise 64 distinct isomers; for ex-
ample, attack of arachidonic acid yields four regioisomers (positional
isomers), each of which can yield a further eight isomers, together
with diastereomers — making possible 64 F2-IsoPs. The two side
chains for the prostaglandins are predominantly in the trans confor-
mation relative to the cyclopentane ring, whereas they exist in the15-F2t-IsoP 
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trans conformation is favored thermodynamically, the more kinetical-
ly favored cis results for IsoPs because of the bicycloendoperoxide ox-
idation intermediate.
IsoPs are released in free form from the esteriﬁed membrane
lipids upon cleavage by phospholipases. In free form, they can then
circulate or be excreted (primarily via urine, but also via bile).
They can also undergo further metabolism, most notably yielding
dinor products (via beta-oxidation); for example, 8-isoPGF2α can
be metabolized to 2,3-dinor-8-iso-PGF2α (see Fig. 2), whose delta-5
double bond can then be reduced to 2,3-dinor-5,6-dihydro-8-iso-
PGF2α (Roberts et al., 1996). The preﬁx “nor” (normal) refers to re-
moval of one carbon and accompanying hydrogen atom (demethyl-
ation or removal of a methylene group); for IsoPs, dinor metabolites
have two methylenic carbons removed from the carboxy-terminus
side chain.
The dinor metabolites can be used as markers themselves, as they
serve as surrogates for the parent IsoPs. They are sometimes excreted
at levels exceeding those of parent IsoPs by several fold (Burke et al.,
2000; Nikolaidis et al., 2011). For the purposes of the BioSCIM
concept, the dinor metabolites might be suitable for measuring and
summing together with IsoPs to achieve a more comprehensive and
larger signal of oxidative stress. Some methods capture all dinor-
dihydro metabolites in one chromatographic peak (Davies et al.,
2006). Urinary excretion of the dinor metabolites varies depending
on the overall beta-oxidation activity. In one study, for example, the
ratio of urinary dinor-8-epi-PGF2α to 8-epi-PGF2α was 15 (33.72±
5.80 nmol/L versus 2.11±0.41 nmol/L), with 2,3-dinor-5,6-dihydro-
8-epi-PGF2α at 16.43±5.62 nmol/L. In contrast, in another study
involving 845 women serving as controls in the Shanghai Women's
Health Study (SWHS), the levels of the dinor metabolites were
roughly 30–50% those of the parent F2-IsoP (Dorjgochoo et al., 2011);
but in a related SWHS study, 2,3-dinor-5,6-dihydro-15-F2t-IsoP
was found to be a more sensitive and speciﬁc measure of oxidative
stress than the parent 15-F2t-IsoP (Dai et al., 2009; Dai and Zhu,
2009). As the level of oxidative stress increases, the relative levels
of dinor metabolites can decline if beta-oxidation becomes impaired.
This variability supports a rationale for measurement of the parent
IsoP together with its dinor metabolites (Nourooz-Zadeh et al.,
2006).
IsoPs are viewed as providing an integrated measure of systemic
oxidative stress because they are produced in every tissue of the
body — as a direct consequence of numerous processes that generate
oxidative radicals; they are even excreted via the breath (Janicka et
al., 2010). Large quantities are excreted via urine, where the concen-
tration can be 30–40 times higher than in plasma. The different series
and isomers of IsoPs can all be formed in different and varying pro-
portions — and metabolized at different rates. Even though their for-
mation is predominately by free-radical oxidation, this process is
inﬂuenced by the type and anatomical location of the speciﬁc oxida-
tive stress. The spatial distribution of the various isomers in the
body is thereby also affected.
Although each of the IsoP classes directly reﬂects the free-radical
oxidation of a single species of polyunsaturated fatty acid (e.g., F2-
IsoPs derive from arachidonic acid), it is widely assumed that polyun-
saturated fatty acids (PUFAs) are oxidized indiscriminately, and that
formation of a given class of IsoPs from the oxidation of one species
of PUFAs serves as a surrogate for other PUFAs.
Since a signiﬁcant portion of IsoPs are incorporated into structural
lipids (e.g., membrane lipid rafts and caveolae), a reservoir exists
from which free IsoPs can be continually liberated; it is believed
that once IsoPs incorporated in cellular membranes are peroxidized
that the membranes become more rigid, compromising permeability
and altering signal transduction (Dietrich-Muszalska and Olas,
2009). This moderates the free concentrations, serving to prevent
fast ﬂuctuations in urinary levels. This partly contributes to the utilityof urinary IsoP levels as a measurement index. Other characteristics of
IsoPs contributing to their usefulness as biomarkers includes their
chemical stability, comparatively low variation in intra- and inter-
individual variations in excretion rates, and relative resistance of ex-
cretion rates to changes in diet and time of day (Cracowski et al.,
2002; Il'yasova et al., 2004).
IsoPs can serve dual roles — not just as passive biomarkers of
exposure but also as active mediators or promoters of effects
(Cracowski and Durand, 2006; Crankshaw and Rangachari, 2003;
Morrow, 2006). IsoPs may play extremely complex roles as both in-
hibitors and activators in regulating a wide spectrum of biochemical
pathways that feed into numerous physiological outcomes (Niki,
2008, 2009); they can also serve as incidental ligands, such as for
eicosanoid receptors (e.g., the thromboxane receptor). While this as-
pect is far too complex to summarize here, some of the complexity
and unknowns surrounding the biochemical functions of IsoPs is
illustrated by their complex roles in the functioning of blood platelets
(Ting and Khasawneh, 2010).
IsoPs are believed to play major roles in a broad spectrum of acute
and chronic inﬂammatory diseases, all of which may underlie in par-
ticular the general process of aging; see Section 8: Factors and vari-
ables affecting regulation of IsoP production: disease, lifestyle, and
genetics. An overview of the inﬂammatory response in relation to
the eicosanoid cascade is provided by Helmersson (2005). IsoP levels
serve as an integrated response from the cumulative exposure to
many forms of stress, spanning the range from chemicals to non-
chemicals (e.g., psycho-social stress). Indeed, an exposure measure
that encompasses psycho-social stress (important especially in asses-
sing environmental justice) persists as another unmet need in cumu-
lative risk assessment (Lewis et al., 2011; NRC, 2011). Moreover, as
noted by Lewis et al. (2011), “…it is difﬁcult to imagine how the effec-
tiveness of interventions could be assessed effectively without a met-
ric for estimating targeted, cumulative risk reduction”. IsoPs play dual
roles, as biomarkers of oxidative stress and as mediators of inﬂamma-
tion. They are both effects-based and stressor-based (see Supplemen-
tary materials). They also reﬂect cumulative exposure. The problems,
limitations, and caveats regarding selection of biomarkers of oxida-
tive stress are discussed by Halliwell (2009).
A major postulated strength BioSCIM in general (especially when
targeting IsoPs) is that it would serve to integrate the effects from
all forms of bona-ﬁde exposure. It would not rely on the conven-
tional approach of compiling recollected (and often subjective or in-
accurate) exposures from test subjects via self-reporting and
historical records; but the interpretation of BioSCIM results could
be aided by such exposure data. A major potential confounder of
the approach is whether a few individuals among a population
may have extraordinarily high changes in excretion levels of a bio-
marker sufﬁcient to disproportionately inﬂuence the collective data
from the entire population.
A major objective in the conceptualization of BioSCIM set forth
here is to catalyze discussion, debate, and research regarding its
feasibility. IsoPs were selected as candidate biomarkers most likely
to yield results because of their established use in clinical research
and a sizeable body of published data — a summary of which is
presented in this document. In reality, any number of other bio-
markers may also prove useful. Ultimately, a spectrum of biomarkers
could form the basis of a comprehensive BioSCIM program. These
markers could comprise those that integrate exposure/effects across
a broad spectrum of biological processes as well as those that reﬂect
unrelated states of more speciﬁc stress or disease. IsoPs are presented
here in part as an illustration of the evaluation process needed for
implementation. The only limitation to incorporating more
biomarkers (especially those of more speciﬁcity) is whether they
meet the criteria in Table 1. IsoPs reﬂect a widely integrative measure
of cumulative and aggregate exposure/effects relative to the whole
body.
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The chemistry and nomenclature of IsoPs are extremely complex.
IsoPs also are but a small part of the vast eicosanoid network (those
fatty acids containing 20 carbons — and closely related fatty acids).
There are three different chemical naming conventions for the 64
different isomers that originate just from arachidonic acid: the sys-
tems of Taber et al., Rokach et al., and Mueller (Nikolaidis et al.,
2011). This has added considerable confusion to the published liter-
ature and perhaps has also sometimes led to misrepresentation
(Mueller, 2010; Murphy and Fahy, 2010). As one example, 15-F2t-
IsoP reﬂects the Taber naming convention (Taber et al., 1997); see
Fig. 2. The ﬁrst number refers to the location of the acyl side-chain
hydroxyl group (i.e., 5, 8, 12, or 15). The subscript number after
“F” refers to the number of unsaturated bonds in the side chains;
other descriptors denote the stereochemistry of the ring hydroxyl
group(s). The 5- and 15-series tend to be the most abundant IsoPs
because the precursors to the 8- and 12-series are more prone to
further oxidation.
15-F2t-IsoP is one of the key isoprostanes studied, largely because
it was the ﬁrst available commercially. It is the same as 8-isoPGF2α
and 8-epi-PGF2α and is also called isoprostaglandin F2α type III or
iPF2α-III (Rokach et al., 1997, 2004); see Fig. 2. The different “types”
are a function of the PUFA from which they are derived: e.g., arachi-
donic, eicosapentaenoic, or docosahexaenoic acid. Taber's nomencla-
ture follows conventional chemistry rules, conforms to existing
prostaglandin naming conventions, and has been accepted by the
IUPAC. Some of the naming conventions do not accommodate com-
monalities among speciﬁc IsoPs with respect to biochemical origin
or especially with respect to biological activities (Mueller, 2010).
Compared with the prostaglandins, where the unsaturated side
chains are all trans to the cyclopentane ring, the conformation for
the IsoPs is exclusively cis (see Fig. 2). Succinct and authoritative dis-
cussions of nomenclature are provided by Nikolaidis et al. (2011) and
by PiŁacik et al. (2002), among others. Note, however, that through-
out the following discussion and Supplementary materials, little at-
tempt was made to standardize the variety of naming conventions
used in the articles under discussion.
An extensive listing of over 100 IsoPs (common names, systematic
names, synonyms, structures, formulas, molecular mass) can be
found at LIPID MAPS (2008, 2011). Other types of IsoPs (and IsoP-
like compounds) are produced in vivo (e.g., cyclopentenone-based,
neuroprostanes, isofurans), but the focus of the work reported here
is on the more stable forms of IsoPs that are extensively excreted
via urine — primarily the F2-series.
Isoprostanes were originally called “iso-prostaglandins” but their
origin within the body is totally distinct — as cyclooxygenase is gen-
erally not involved in their formation. Their production is therefore
not affected by the medications that can regulate prostaglandin pro-
duction (i.e., non-steroidal anti-inﬂammatory drugs [NSAIDs] or glu-
cocorticoids). The in vivo formation of IsoPs in humans was ﬁrst
reported by Morrow et al. (1990a, 1990b, 1992). Signiﬁcantly, while
IsoPs act as biomarkers of oxidative stress, they can simultaneously
also directly act as pro-inﬂammatory agents themselves. For example,
they are potent broncho- and vaso-constrictors. In this sense, as both
products and mediators of disease, they are biomarkers of both expo-
sure and effects (sequelae of oxidative stress — not always harmful
and sometimes essential). They may well cause some of the very pa-
thologies that they are used to measure.
While COX-inhibitors (e.g., NSAIDs) repress the formation of pros-
taglandins, they have no direct effect on the formation of IsoPs, which
are produced by a non-enzymatic COX-independent route. IsoPs are
formed as racemic diastereomers. An exception regardingprostaglandin
formation is urinary PGF2α (as well as ent-PGF2α), trans-side-chain
products that seem to be formed primarily via the same non-
enzymatic pathway used for IsoP rather than from COX. Thisprostaglandin and its enantiomer are therefore also measures of free-
radical induced oxidative stress— as opposed tomarkers of COX activity
(Yin et al., 2007).
The discovery of IsoPs was ﬁrst recounted by Morrow et al.
(1990a, 1990b). Comprehensive reviews that cover all aspects of
IsoPs (nomenclature, biosynthesis, chemistry, metabolism, analysis,
roles as markers and mediators in oxidative stress and disease,
and cell-signaling) began to appear in the 1990s. Among the many
excellent reviews are the following, with perhaps one of the more
comprehensive being that of Jahn et al. (Basu, 2008; Basu and
Helmersson, 2005; Cracowski and Durand, 2006; Dalle-Donne et
al., 2006; Fruhwirth et al., 2007; Jahn et al., 2008; Kom, 2007;
Milne and Morrow, 2006; Milne et al., 2005, 2008, 2011; Montuschi
et al., 2007; Morrow, 2006; Nälsén, 2006; Nikolaidis et al., 2011;
Nourooz-Zadeh, 2008; PiŁacik et al., 2002; Praticò, 1999; Praticò et
al., 2004; Roberts and Fessel, 2004; Roberts and Milne, 2009; Rokach
et al., 2004; Yen, 2010; Yin, 2008). Excellent graphics showing bio-
synthetic pathways are reprinted in many reviews (e.g., Jahn et al.,
2008; Morrow et al., 1990a).
Worth noting is that 15-F2t-IsoP (8-isoPGF2α) is the most fre-
quently studied IsoP, not necessarily because of any inherent impor-
tance, but because of its early and widespread commercial
availability as an analytical reference standard. Indeed, other IsoPs
and their dinor metabolites may eventually prove more important
as biomarkers. Furthermore, prevalence at local sites or release in
speciﬁc tissues may not necessarily reﬂect abundance in urine.
Urine provides a measure of lipid peroxidation integrated over a pro-
longed interval. In this review, emphasis was placed on examining
the published literature on urinary excretion rather than on levels
in plasma or other tissues. Data on plasma levels may not have rele-
vance with respect to the types and levels of IsoPs that might
occur in sewage. Data on fecal excretion (including bile) would also
be relevant but is almost non-existent [see Section 10.4: Biliary (and
fecal) excretion].
A very brief overview of the larger context of lipidomics in which
IsoPs exist is useful in appreciating that they also serve in many re-
spects as surrogate measures for many other oxidized phospholipids
(oxylipid) biomarkers (for more discussion, see the Supplementary
materials). The roles of IsoPs with respect to oxylipids are covered
in the comprehensive review of Bochkov et al. (2010). The diverse
roles in disease played by the many products of lipid peroxidation
have been comprehensively covered in a number of reviews (e.g.,
Negre-Salvayre et al., 2010; Niki, 2009; Palmieri and Sblendorio,
2007; Spickett et al., 2010).
Many of the complex aspects of IsoPs are not a focus of this
paper, especially since they are amply covered in the reviews cited
above. For the purposes of this paper, the most important aspect is
the urinary excretion of IsoPs — as it relates to the proposed moni-
toring of IsoPs in sewage as a fast and non-invasive means to mea-
sure the collective contributions of a biomarker of stress from small-
area populations.
7.3. Isoprostanes as biomarkers of both exposure and effects
IsoPs serve as retrospective markers of whole-body oxidant injury
(e.g., pathophysiological markers of lipid peroxidation) as well as
prognostic markers of potential injury (e.g., as mediators of oxidative
stress such as involved with cardiovascular diseases). IsoPs serve as
both time-integrative indicators and mediators of oxidative stress.
They therefore not only have diagnostic value for disease states but
also prognostic value for predicting pathologic conditions. IsoPs not
only reﬂect oxidative stress, they are also involved with causing stress
(most directly and fundamentally simply by altering the physical
structure, integrity, and ﬂuidity of cell membranes by changing steric
properties). At the same time, it is important to keep in mind that
IsoPs are also involved in a range of normal processes involved with
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and other tumor suppressors required in apoptosis). As such, they can
be elevated as a result of non-pathological eustress and seemingly
healthy activities (such as pregnancy and exercise), and most basical-
ly, by basal metabolism; they can also display reductions in levels
during diseased states — as a result of inhibition of protective basal-
level production.
IsoPs integrate information from a very wide spectrum of biolog-
ical events across the entire body. They can be viewed and utilized
as biomarkers of: exposure (actual internal dose of a xenobiotic), ef-
fect (response, disease, altered homeostasis, structure, or function),
and susceptibility or vulnerability (reﬂecting stress or status or
change in homeostasis or physiological dysfunction — e.g., polymor-
phisms). They can facilitate or assist in diagnosis (in medicine, epi-
demiology, or forensics), prognosis, and therapeutic intervention
(Crimmins and Vasunilashorn, 2011). An advantage of biomarkers
of stress such as IsoPs is that a portion of the processes they serve
to measure can emanate from disease that has yet to manifest itself
as a clinical phenotype and could not otherwise yet be detected by
clinical assessment.
A partial listing of pathologies in which IsoPs are elevated is sum-
marized in Basu (2007, Table 1); these include cardiovascular dis-
ease, hypertension, diabetes, hepatic cirrhosis, obstructive
pulmonary disease, obesity, neurodegenerative diseases, and asthma;
inﬂammation, vasoconstriction, and platelet aggregation are com-
mon modes of both acute and chronic action. At least a portion of
the biological activity of IsoPs is believed to occur as a result of IsoP
acting as incidental ligands for certain inﬂammatory prostaglandin
receptors (Song et al., 2009). IsoPs therefore serve as an integrated
measure of a wide spectrum of combined disease states as well as
non-disease stress, such as poor nutrition, exposure to smoke
(Ahmadzadehfar et al., 2006), or other physicochemical stressors
such as drugs that cause idiosyncratic reactions (e.g., Lu, 2006).
Their production can be reduced by other stressors such as moderate
exercise, or increased, such as by over-training (Margonis et al.,
2007). Therefore, not all IsoP production results from disease, and
their production can be reduced by certain activities; so data have
the potential to become confounded. There has also been insufﬁcient
research on IsoP metabolism and excretion as inﬂuenced by genetics,
gender, age, lifestyle, or other non-disease variables. These factors
could all add a layer of complexity and unknowns to the interpreta-
tion of IsoP levels in sewage.
By targeting a biomarker of general oxidative stress, the follow-
ing variables are automatically fully accommodated. In risk assess-
ments, each of these variables must normally be modeled, and in
the process must account for numerous unknowns: (i) exposure to
ALL stressors (chemical and non-chemical), (ii) actual dose from
each exposure event, (iii) additive and interactive effects from all
stressors (additivity, synergism, antagonism), (iv) metabolic accom-
modation (induction or upregulation of detoxication pathways), (v)
metabolic activation (induction or upregulation of intoxication path-
ways), (vi) intra-individual and inter-individual variability (genetic,
such as single-nucleotide polymorphisms [SNPs], and epigenetic),
(vii) prior exposure history, (viii) windows of vulnerability, and
(ix) diurnal ﬂuctuations in metabolism and gene expression —
among others.
8. Factors and variables affecting regulation of IsoP production:
disease, lifestyle, and genetics
An understanding of a biomarker's synthesis pathways and mech-
anism of control is needed to appreciate the limitations in interpret-
ing BioSCIM data. Halliwell and Lee (2010) discuss some of the
many factors that regulate IsoP production. Various junctures along
the pathways of IsoP formation can be affected by different endoge-
nous biochemical processes or exogenous stressors. For example, ifesteriﬁed IsoP is being continually created by oxidative assault but
the phospholipases have been inhibited, then IsoP levels in plasma
(and therefore presumably urine) could decline (with a concomitant
accumulation of lipid-bound IsoPs in cell membranes). Likewise, if
beta-oxidation processes were to be inhibited (thereby inhibiting
the formation of dinor metabolites), free IsoP levels could rise. The
major question is whether the rate of IsoP production accurately re-
ﬂects the rate of lipid peroxidation. In reality, the free IsoP production
rate may vary wildly among individuals as a function of a broad spec-
trum of variables — not the least of which is what type of stress each
is sustaining and whether the stress is acute or chronic.
Studies have examined possible associations of IsoPs with a wide
spectrum of diseases — as both passive and active markers. A num-
ber of articles provide summaries (e.g., Schwedhelm et al., 2007).
Many studies, especially large epidemiological studies, have tar-
geted multiple biomarkers and multiple risk factors. This makes it
difﬁcult to provide straightforward summary of the data on the as-
sociation of IsoP levels with particular diseases. An example of a
larger-scale study comes from the Framingham Heart Study,
where urinary 8-epi-PGF2α levels (normalized to creatinine) for
2828 subjects were found to most strongly correlate with smoking,
diabetes, and body mass index (Keaney et al., 2003). Corroborating
many other studies, a deﬁnitive association with gender was shown,
where urinary 8-epi-PGF2α levels for women were higher than in
men — by 16%. The strongest association, as also seen in many
other studies, was for smoking, where smokers had 65% higher
mean levels than nonsmokers. One factor that has shown variable
correlations was age, which in this case appeared to be negatively
associated. Another example comes from a 299-subject cohort of
the Insulin Resistance Atherosclerosis Study (IRAS), where four uri-
nary F2-IsoPs were correlated with gender, ethnicity, smoking,
physical activity, BMI, waist circumference, weight change, and dia-
betes (Il'yasova et al., 2011).
Understanding the action of IsoPs as facilitators of disease may be
hampered by the possibility that their actions are mediated in concert
(or in series) with numerous other IsoPs at a variety of receptors and
at requisite absolute and relative concentrations at disparate cellular
locations. IsoP excretion levels sometimes seem counterintuitive or
paradoxical — increasing as a result of activities generally associated
with healthy lifestyles or activities, and other times decreasing as a
result of seemingly unhealthy states. One example shows an associa-
tion between urinary F2-IsoP and BMI following a U-shaped curve,
with the highest urinary IsoP levels resulting at both the lowest and
highest BMI values (Narukawa et al., 2011); with the IRAS cohort, uri-
nary F2-IsoPs were inversely associated with weight gain (Il'yasova et
al., 2011). Also worth noting is that randomized, double-blind,
placebo-controlled intervention clinical trials that follow IsoP levels
are very rare; most studies are observational. In general, even when
statistically signiﬁcant changes in IsoP levels are seen in clinical stud-
ies, they are rarely dramatic.
Some representative studies targeted at correlating speciﬁc dis-
eases or stress with IsoP levels are summarized in Table 2 and dis-
cussed in more depth in the Supplementary materials. The emphasis
has been placed on studies that monitored urine levels rather than
plasma levels. Also summarized are studies of those variables that
may serve to confound the interpretation of BioSCIM data. Many fac-
tors can interact, sometimes serving to thwart generalizations; con-
tradictory studies are not infrequent. Correlations with given factors
can also vary among the various parent IsoPs and their metabolites.
IsoP levels not only can correlate with disease activity or severity,
but also act as mediators of disease progression.
9. IsoP analysis and complications in comparing published data
Of all the factors involved with developing a BioSCIM approach
based on IsoPs, the one that would contribute some of the greatest
Table 2
Disease or health factors that correlate with IsoP levels.a
Disease or health factor Relative urinary IsoP levels (versus controls)
Metabolic syndrome (multiple risk factor syndrome)
• Obesity (and higher BMI
and waste circumference)
Several fold to an order of magnitude higher;
can be a function or baseline status; levels
can reverse with dieting.
• Diabetes Roughly 3-fold higher; even higher levels with
glycemic excursions.
• Cardiovascular disease (CVD) Elevated for most forms of CVD; also correlate
with other markers of CVD and with severity
Smoking Several fold higher and strongly correlated;
gender differences occur; also higher with
passive smoking; sensitive to starting
and stopping.
Pulmonary disease and asthma Levels are often higher, but strongest
correlations are in exhaled breath
condensate (EBC).
Psychological stress and
depression
Levels seem to vary inversely with positive
mood scores.
Cognitive decline and
Alzheimer's disease
Evidence points to possible correlation.
Alcohol consumption One of the strongest correlations; levels can
increase many-fold; most data, however,
derive from plasma.
Cancer Increased levels with some cancers (e.g., liver,
lung, prostate), but not all (e.g., breast)
Associations with other diseases
or conditions
Sometimes dramatic correlations with:
rheumatoid arthritis, Lyme disease, chronic
fatigue syndrome, autism, pregnancy, Dengue
fever, ischemic stroke.
Exercise Complex correlations (both positive and
negative) depending on level and duration
of exertion.
Drug usage correlations Levels can be elevated or depressed during
treatment with certain drugs (e.g., valproic
acid) or consumption of illicit drugs; many
studies show mixed correlations.
Associations with various
non-stressor variables
• Gender Signiﬁcant gender differences are often seen
but can reverse among studies.
• Age Levels of parent IsoPs often increase with age
(beginning at age 5).
• Genetics/heritability Environmental factors seem to have a larger
inﬂuence than genetics.
a See Supplementary materials for discussion and supporting references.
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analysis. Several factors contribute to this uncertainty, primarily by
adversely affecting variance in both accuracy and precision, as well
as in impacting decisions as to exactly what chemical species of IsoP
should be targeted for monitoring. As emphasized earlier, minimizing
analytical variance will prove to be the key in being able to distin-
guish stress signals from “normal” or “baseline” levels.
Signiﬁcantly, of the numerous methods reported in the literature
and developed for a wide spectrum of tissues and ﬂuids from
humans, animals, and plants, none has ever been applied to sewage,
which will undoubtedly pose yet additional challenges for sampling
and analysis; some of these challenges have already been discussed
(Daughton, 2012). Important to recognize is that no biomarker of
stress, disease, or health has ever been targeted in any chemical char-
acterization study of sewage.
IsoPs are quantiﬁed primarily with the use of either mass spec-
trometry (coupled with liquid or gas chromatography — LC/MS or
GC/MS) or competitive immunoassay (RIA or ELISA); representative
LC/ESI-MS/MS chromatograms for some isoprostanes (among others
for various prostanoids and dihydroprostaglandins) can be seen in
Masoodi and Nicolaou (2006). While the analytical results from
these various methods correlate well in some studies (e.g., Carraro
et al., 2010; Devaraj et al., 2001), they do not in others (e.g.,
Callewaert, 2004; Liang et al., 2003). Since ELISA has clearly beenthe method of choice in terms of cost and speed (a critical attribute
of any method intended for widespread, routine use), it would even-
tually need to be corroborated by an orthogonal approach, probably
involving MS, especially given the bias in immunoassay that can be
introduced by cross-reactivity.
The IsoP most targeted in the literature for analysis in urine is
15-F2t-IsoP. The attributes of the F2-class of IsoPs that make them
ideal as biomarkers are summarized by Montuschi et al. (2004),
and include: (i) chemical stability, (ii) generation speciﬁcally in
vivo by peroxidation and little artefactual formation in urine, (iii)
low limits of detection can be achieved in various tissues and ﬂuids,
(iv) levels increase substantially during oxidative stress, and (v)
levels are little affected by lipid content of diet. They also undergo
rather fast elimination from the body (Cracowski et al., 2002), and
artefactual formation in urine is minimal because of the absence of
arachidonic acid (Kom, 2007). The F2-IsoPs have been shown to be
stable in urine for over a week at room temperature (Praticò et al.,
1998) or for up to 3–6 months when stored at −20 to −80 °C
(Ohashi and Yoshikawa, 2000). While these studies indicate that
sample transport and storage might not pose problems, the vari-
ables added by the presence of fecal materials leaves open the ques-
tion of IsoP stability is stored sewage (especially with the potential
for microbial degradation). This topic has never been evaluated
and marks one of the priorities for establishing IsoPs as a target bio-
marker suitable for BioSCIM.
Acquisition of accurate and reproducible analytical data is compli-
cated by the fact that 15-F2t-IsoP (as well as probably all other IsoPs)
undergoes extensive but variable inter-individual glucuronidation
during metabolism. To eliminate this source of variability, samples
might ﬁrst need to be treated with glucuronidase prior to analysis
in order to release the free parent 15-F2t-IsoP. Enzymatic cleavage of
the glucuronide has been shown to yield up to 80% more free 15-
F2t-IsoP in urine (Oxford Biomedical Research, 2008); the role of
IsoP conjugates has been addressed in more detail in Section 10: Iso-
prostane excretion data. Another challenge, especially in comparing
data across published studies, is the unknown degree to which vari-
ous IsoP isomers (and isobaric analogs such as the prostaglandins)
are resolved during mass spectrometric analysis. Some data are un-
doubtedly biased high because of the overlap of multiple isomers in
a chromatographic peak comprising what might be mistakenly
thought to represent a single isomer.
Yet another factor that complicates the intercomparison of pub-
lished data on urinary levels of IsoPs is the numerous dimensional
measurements used to express concentrations. These include both
mass and molar dimensions, expressed in terms of either absolute
levels (such as mass or moles per unit volume) or relative, dimen-
sionless levels (generally normalized to creatinine); the use of creat-
inine in clinical chemistry poses a variety of its own problems and
would introduce yet more variability for BioSCIM data (Daughton,
2012). Unlike clinical use, where a biomarker's urinary concentration
is often normalized to creatinine (to compensate for urine dilution —
a problem caused solely by reliance on spot urine samples instead of
24-h samples), the value relevant to modeling anticipated levels of a
biomarker in sewage is the total per capita excreted quantity,
expressed on the basis of absolute mass or moles. Values normalized
to creatinine are problematic to accurately translate into absolute
rates of daily excretion. This problem can be most readily seen with
the gender discrepancies often noted for urinary IsoP levels, where
levels normalized to creatinine are usually higher in women. This
may actually represent an inherent bias introduced by the fact that
women usually possess less lean muscle and therefore excrete less
creatinine (Daughton, 2012). Unfortunately, most studies express uri-
nary IsoP excretion normalized to creatinine rather than on a volume-
concentration basis; this confounds the interpretation of IsoP excre-
tion data (as well as data for endogenous biomarkers in general) for
the purposes of BioSCIM.
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dated, standardized method, although a method standardized for
urine could possibly be modiﬁed and adopted for raw sewage.
Method standardization is an unmet need with most biomarkers. An
example of a major aspect of standardization (inter-laboratory,
inter-method comparison) is shown by the work of the European
Standards Committee on Urinary (DNA) Lesion Analysis (ESCULA)
for the urinary biomarker of oxidative stress derived from DNA — 8-
oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) (Evans et al., 2010).
Currently, two major approaches for IsoP analysis involve immu-
noassay and hyphenated versions of mass spectrometry. A number
of commercial immunoassays are available (such as those from Cay-
man Chemical, Detroit R&D, Enzo Life Sciences, Kronos Science Labo-
ratory, Northwest Life Science Specialties, Oxford Biomedical
Research, and OxisResearch), few of which have been inter-
compared or compared versus mass spectrometric methods. Numer-
ous methods using GC/MS or LC/MS have been published, but all
have been separately developed for disparate research programs in
a variety of ﬁelds. Nearly all methods rely on some form of prior sep-
aration or cleanup, with a wide spectrum of speciﬁcities — ranging
from solid phase extraction or thin-layer chromatography to immu-
noafﬁnity chromatography (IAC). IAC for IsoP analysis was ﬁrst ex-
plored in the 1990s (Bachi et al., 1996). IAC has shown potential in
sample preparation for providing highly standardized, intercompar-
able data as a result of its very high speciﬁcity for targeted IsoP ana-
lytes (Sircar and Subbaiah, 2007; Tsikas, 2010b; Tsikas et al., 2003).
Artefactual interferences are problematic for all IsoP methods not
using IAC, even when using internal standards (e.g., Mas et al.,
2010a). Only more recently has effort been devoted to developing
methods (generally based on HPLC) requiring minimal sample prep-
aration (e.g., Saenger et al., 2007).
Comprehensive inter-method or inter-laboratory comparisons are
rare. Comparisons of methods based on immunoassay with those
based on mass spectrometry are particularly lacking (e.g., Tsikas,
2010a). Poor correlation or high bias has been discussed in a number
of studies (Bessard et al., 2001; Huang et al., 2002; Il'yasova et al.,
2004; Klawitter et al., 2011; Liang et al., 2003; Saenger et al., 2007;
Smith et al., 2011). Some of the possible causes of variability and
some caveats regarding sampling, sample preparation, and analysis
have been discussed (e.g., Callewaert, 2004; Jones, 2005).
The questionable precision and accuracy of the commercial immu-
noassay kits (versus MS-based methods) greatly diminishes the pos-
sible utility of a large portion of the published literature, especially
clinical research that has heavily relied on the convenience of these
kits. Inadequate sample puriﬁcation and cross-reaction among IsoPs
are major limitations. Even when good correlations between immu-
noassay and MS methods are reported, the immunoassays are always
found to yield results biased high — by at least 100% (Carraro et al.,
2010; Yan et al., 2007).
A number of comprehensive reviews on IsoP analysis are available
(e.g., Berdeaux et al., 2006; Davies, 2009; Lawson and FitzGerald,
2002; Liang et al., 2003; Liu et al., 2009; Milne et al., 2007;
Nikolaidis et al., 2011; Yin, 2008). Advancements in the trace analysis
of IsoPs in biological matrices have been infrequent. One analytical
approach, developed by Eggink et al. and further developed by
Kretschmer et al., makes use of a new derivatization reagent for
HPLC (Eggink et al., 2010; Kretschmer et al., 2011). Progress is being
made toward automating IsoP analysis, via HPLC/MS (Bai et al.,
2011). Others are working on increasing the sample throughput and
accuracy of methods (e.g., Dahl and van Breemen, 2010; Langhorst
et al., 2010).
Regardless of the dearth of research on method comparability,
the various F2-IsoPs seem to be able to proxy for each other. This
is important with respect to another complication associated with
analysis — namely, the separatory resolution of the numerous F2-
isomers possibly present. The actual scope of an F2-IsoP method isoften not clear — it is sometimes unknown whether a method
might be speciﬁc for a single isomer or whether it is capturing mul-
tiple isobaric species. With that said, it has often been proposed that
it might prove more useful to purposefully capture multiple F2-
isomers together (or better, all F2-IsoPs in toto, or perhaps even
include F2-dinor metabolites) in a single analysis rather than target
discrete isomers. This approach would greatly improve method
sensitivity and lessen variability. This important topic has been
emphasized in many papers (e.g., Cracowski et al., 2002; Halliwell and
Lee, 2010; Mori et al., 1999a; Nikolaidis et al., 2011; Schwedhelm et
al., 2007; Taylor et al., 2008; Tsikas et al., 2003).
Uncertainty in exactly which isomers are captured by a method is
often indicated with the use of generic expressions such as “F2-isomers”.
A conﬂated class-wide measure would increase the sensitivity of the
method and ensure that the origins of oxidative stress are more widely
represented. This is especially true since current knowledge is insufﬁ-
cient to determine which isomer(s) best reﬂects oxidative stress,
which is the most potent mediator of stress, or which is most abundant
in urine (Cracowski et al., 2002). Moreover, the relative contributions
from individual isomersmay changewith time, depending on the health
status of an individual (individual F2-IsoP isomers may originate from
different diseases and may have different biological effects), and the dif-
ferent isomers may experience different metabolic clearance rates. Re-
gardless, the fact that different methods capture different types and
numbers of F2-IsoP isomers can serve to inﬂate or deﬂate the apparent
range of urinary IsoP values far beyond what would otherwise be
achievable with a standardized method.
An extremely broad array of methodologies and QA/QC has been
employed in IsoP analysis. The most important insight to gain from
the extensive published literature involving IsoP analysis is that the
data from different studies (even those using the same basic analyt-
ical approach) should probably not be inter-compared with respect
to absolute concentrations. The value of these data with respect to
BioSCIM currently resides in the perspective they provide on the
precision (and the maximum range of values) that might be
expected from any given method.
10. IsoP excretion data
Despite the disparities in the way published data on urinary IsoP
levels are reported, these data are valuable for determining the po-
tential utility of IsoP in a BioSCIM application. These data address
two major unknowns: determining (i) how broad a reference interval
might be for urinary IsoP levels from a “normal” population, and (ii)
the magnitude of the excursions outside the reference interval for uri-
nary IsoP levels from “non-normal” (e.g., diseased or stressed) indi-
viduals. The latter must be signiﬁcantly greater than the former to
be detected.
While the magnitude of the range of the data from an individual
study is useful, the magnitude of the range for data compiled across
studies, which would probably be very large, is not meaningful be-
cause of signiﬁcant differences in analytical methodologies. The
broad range in inter-study data distribution is primarily biased by
the inclusion of different IsoP isomers in different methods; this is es-
pecially evident in the discrepancies between the data from immuno-
assay and mass spectrometric methods.
Much of the IsoP data collected from clinical and epidemiological
studies has used immunoassay. These data may be biased high be-
cause of cross-reactivity with numerous other isomers and may
have larger variance because of intra- and inter-method variability.
A large portion of the IsoP studies conducted with human subjects
targeted IsoP levels in blood (generally plasma or serum). IsoPs in
blood could be viewed as mirroring acute (real-time) overall stress,
while urinary levels serve to integrate stress over time (both acute
and chronic). Blood levels are not necessarily relevant with respect
to predicting the levels or variance of IsoP excretion in urine (or
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levels are not necessarily reﬂected in urinary levels (Halliwell and
Lee, 2010). Therefore, the focus here is almost solely on urinary excre-
tion of IsoPs. Another limitation of the published data is that most are
obtained from studies that collected spot (convenience) samples, as
true 24-h samples are difﬁcult to obtain. Diurnal variability in excre-
tion will mean that spot sample data is more difﬁcult to extrapolate to
levels that might be expected in sewage.
As previously emphasized, the actual identity of the IsoP(s) tar-
geted in various studies is often unclear and can range from one to
multiple isomers among one or more series of IsoPs. For this reason,
the term isoprostane (or IsoP) or other informal abbreviations (e.g.,
F2-IsoP) are often used in this document in a generic manner, while
fully realizing the lack of rigor. Failure to distinguish IsoP isomers
could be a source of considerable variability when comparing data
across studies. As one example, in a study that targeted ﬁve individual
IsoP isomers, the range in urinary levels across the isomers spanned
nearly an order of magnitude: from 0.532 μg/day (for 15-epi-iPF2α-
III) or 0.592 μg/day (for iPF2α-III) up to 5.169 μg/day (for iPF2α-VI)
(Yan et al., 2007).
Another factor treated irregularly across studies is the importance
of IsoP conjugates in urine. Excretion of conjugates apparently varies
between individuals — ranging from little up to 80% of the total IsoP
present (Kadiiska et al., 2005b; Yan et al., 2010). Although some stud-
ies report the use of a pretreatment hydrolysis step using glucuroni-
dase, others make no mention of whether measurement was made
for free or total IsoP. Conjugates, however, may not actually have
much impact with respect to acquiring data for BioSCIM. Even if sub-
stantial portions of IsoP are excreted as glucuronide conjugates, it is
possible these will undergo in situ hydrolysis by the glucuronidase
activity present in sewage. While most studies show glucuronidase
activity in activated sludge, little attention has been paid to raw sew-
age (on during transit to an STP) or even once feces and urine mix in
the toilet. One study, however, shows that estrogen conjugates un-
dergo hydrolysis while in transit to an STP (D'Ascenzo et al., 2003).
The published urinary data from “healthy” subjects (e.g., controls)
conclusively show the continual presence of IsoPs in all urine sam-
ples. These basal levels may not exclusively represent oxidative dam-
age per se, but rather perhaps serve as lipid messengers involved in
myriad endogenous biochemical processes. A certain low basal level
of oxidative stress is probably required to maintain homeostasis and
health; this is one hypothesis often put forth to explain the “antioxi-
dant paradox” — the failure of antioxidant supplementation to reduce
oxidative stress in healthy individuals (Sheikh-Ali et al., 2011). For
example, in the Shanghai Women's Health Study (nearly 75,000
women), supplementation with antioxidants reduced IsoPs only for
those with higher BMIs (Dai et al., 2009; Dai and Zhu, 2009).
The production of elevated IsoPs is often a function of current
health status and the combined stress level. For example, healthy
young adults often show no reduction in IsoP levels when adminis-
tered fruit/vegetables or antioxidants. This is likely because their
IsoP levels are already at the necessary basal maintenance level. Like-
wise, they often also show no increase in IsoP levels under mild stress
(smoking, moderate exercise) because their oxidant defense systems
are robust. This means that with a sufﬁciently low limit of detection,
IsoPs should always be detectable in sewage. The critical question is
whether the increased IsoP levels in sewage, resulting from oxidative
stress, will be sufﬁciently elevated from basal levels to be able to dis-
cern community-wide stress. While any given level of IsoP in sewage
most likely results from the combined contributions from many dif-
ferent stressors and causes, a change in trend might more probably
result from just a few or perhaps a single cause.
Some studies do not reveal a correlation between known oxida-
tive stress and IsoPs in urine. This is perhaps because the levels in
urine are an integrative measure of oxidative stress across the entire
body. Localized stress will not always result in increased urinarylevels. For example, while exhaled breath condensate shows elevated
IsoP levels among certain asthmatic children, IsoP in urine may show
no correlation (Carraro et al., 2010).
Despite the considerable published data on urinary levels of IsoPs
(for both healthy and diseased subjects), the only values that can be
applied directly to predicting the levels of IsoPs that might occur in
raw sewage are the 24-h levels (expressed in terms of mass excreted
per day). Most data on the urinary excretion of IsoPs are reported in
units that cannot be reliably converted to total daily mass (for exam-
ple, because of normalization against creatinine or because of report-
ing on the basis of concentration).With this said, at least seven studies
have reported on the basis of total mass excreted daily. These urinary
excretion data represent basal levels of IsoP production from healthy
individuals and span a combined range from roughly 500–5000 ng/
day, depending on the IsoP isomers captured by analysis; most are
in the range of 1000–2000 ng/day (see in particular: Frost-Pineda et
al., 2011; Mori et al., 1999b; Shi et al., 2007; Stein and Leskiw, 2000;
Tsikas et al., 1998; Yan et al., 2007, 2010). Since this range comprises
extremes from different methods, it could be assumed that use of a
standard method would have probably yielded a narrower range.
Sporadically, some data fall outside the commonly reported
range. One example is the reported daily urinary excretion for 8-
isoprostaglandin F2α at 10 pmol/24 h (3.5 ng/day) (Tsai et al.,
2009), which is over 2 orders of magnitude below the low end of
the range compiled from the seven studies reported above (i.e.,
500–5000 ng/day).
On the basis of creatinine output, levels of F2-IsoPs in normal
human urine are reported to range from 500 to 4000 pg/mg of creat-
inine (Durand et al., 2011), but these data cannot be reliably translat-
ed into total daily outputs. They do, however, reﬂect an inter-method
combined range in the distribution of excretion levels similar in mag-
nitude to that for total daily excreted mass (i.e., 500–5000 ng/day).
This shows that the published data have internal consistency.
One study is unique in that it reports excretion data on the com-
monly used basis (normalized against creatinine) as well as both in
terms of urinary concentration (pg/mL) and in terms of mass excret-
ed per day (μg/day). These unique data serve to illustrate an impor-
tant point. For certain IsoPs, correlations that might not be evident
when excretion is normalized against creatinine (e.g., similar levels
for smokers versus nonsmokers) become apparent when the data
are expressed on another basis, such as in terms of mass excreted
per day (Yan et al., 2007).
10.1. Examples of the maximum magnitude of urinary IsoP levels
The conditions under which the maximum urinary IsoP levels
have been reported may have value in delineating the upper limits
to variation in BioSCIM data resulting from changes in a community's
health status. These reported, enhanced IsoP levels can be roughly
one to two orders of magnitude over basal levels.
Perhaps one indication of a potential maximum magnitude of
change in urinary IsoP levels that might result from oxidative stress
was shown in the original BOSS report, where urinary 8-iso-PGF2α
and 8,12-iso-iPF2α-VI increased 10 and 17 fold, respectively, 7 h
after treatment with the highest carbon tetrachloride dose (Kadiiska
et al., 2005a). Such a dramatic response, albeit in rats, might make de-
tection possible even with a high level of baseline (basal) variability.
Probably the highest reported rates or changes in rates for IsoP ex-
cretion in humans have been documented for genetic disorders.
These excretion rates might serve to describe the absolute upper
limit on IsoP excretion across the numerous other disease states
known to inﬂuence urinary IsoP. One example studied children with
Zellweger syndrome — a rare genetic disorder preventing the proper
assembly of peroxisomes and leading to the accumulation of very
long chain fatty acids in the blood. Five Zellweger children were
shown to excrete 8-Iso-PGF2α at rates over a 100-fold higher than
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mg creatinine (Tsikas et al., 1998).
Although considerable data have been obtained on the correla-
tion of IsoP production in humans with various disease states, few
data are available on the production of IsoP as a result of induced
stress such as with the rodent models used in the BOSS assessment.
One of the few occasions for acquiring such data is during chemo-
therapy infusion. One study followed the urinary production of
four isomers of F2-IsoPs [iPF(2α)-III, 2,3-dinor-iPF(2α)-III, iPF(2α)-
VI, and 8,12-iso-iPF(2α)-VI] during doxorubicin infusion. After 1 h,
the increase in levels ranged from 41% [iPF(2α)-VI] to 62%
[iPF(2α)-III]; all levels returned to baseline after 24 h (Il'yasova et
al., 2010). This type of study is valuable in that it gives insight re-
garding the magnitude of increase in urinary IsoPs that can occur
after a signiﬁcant oxidative insult. It also provides insight on the
speed and sensitivity of IsoP production and rate of return to base-
line. The fact that IsoP returned to baseline levels before doxorubi-
cin had been cleared from the body perhaps meant that
antioxidant defense mechanisms had been quickly up-regulated. In
a follow-up doxorubicin study involving 18 women, the levels of
the four isomers in 10 subjects nearly doubled. It was also shown
that for others who began the study with already elevated IsoP
levels, doxorubicin had little effect (Il'yasova et al., 2011).
Of all common stressors, one responsible for some of the largest
increases in urinary IsoP levels is chronic alcohol consumption asso-
ciated with liver disease. For healthy adults, urinary excretion of
iPF2α-III initially increased about 4-fold from baseline [from
116 pg/mg creatinine to 491 (0–6 h) and 349 (6–12 h)] and then
declined to 202 (12–24 h) after dosing with 0.9 g/kg alcohol. The
levels were also a linear function of dose, increasing from baseline
(50 pg/mg creatinine) to 102 at a dose of 0.2 g/kg alcohol, and to
402 for 0.9 g/kg alcohol (Meagher et al., 1999). Urinary levels
were higher in patients with acute and chronic alcohol-induced
liver disease (ALD) (657 pg/mg creatinine) and higher yet in pa-
tients with combined hepatitis C cirrhosis and ALD (922 pg/mg cre-
atinine versus a baseline of 127 for healthy controls). The highest
levels were from those with acute alcoholic hepatitis (2205 pg/mg
creatinine). This represented roughly a 20-fold increase over con-
trols — one of the largest increases published to date. Excretion of
iPF2α-III was found to be highly correlated with iPF2α-VI, which oc-
curred at much higher levels. The metabolite of iPF2α-III (2,3-dinor-
5,6-dihydro-iPF2α-III) was also markedly elevated.
10.2. Example urinary IsoP ranges for apparently healthy populations
Few studies have been devoted to establishing urinary IsoP levels
for “healthy subjects” or perhaps more appropriately termed “appar-
ently healthy” or “otherwise healthy” subjects. The primary source of
the data for apparently healthy individuals must usually be derived
from their use as controls in clinical studies. Once again, the primary
relevance of these studies for a BioSCIM application is not the abso-
lute levels reported, but rather the variance that is revealed. But
even with studies of apparently healthy individuals, considerable var-
iance is undoubtedly introduced simply by the prevalence of common
factors known to inﬂuence IsoP levels — the very factors that would
ordinarily be reﬂected by BioSCIM — especially smoking, alcohol con-
sumption, exercise, BMI, and age— as well as any of numerous poten-
tial sources of hidden stress. No published studies enlisting otherwise
healthy individuals were found that controlled for all of these major
variance factors, either during recruitment or by statistical means.
Some example data from various studies are brieﬂy summarized
here to provide perspective on the magnitude of variance encoun-
tered. In 323 apparently healthy Japanese, mean urinary 8-IsoP was
0.74±0.03 ng/mg creatinine. Levels were signiﬁcantly higher in
males than females and increased with BMI and frequency of alcohol
consumption (Sakano et al., 2009). A study speciﬁcally designed todetermine a “reference interval” for urinary 8-iso-PGF2α enlisted 34
healthy subjects. The range was 57 to 390 ng/g creatinine with a
mean of 221 ng/g creatinine (Saenger et al., 2007). In a study of 72
healthy young women and men (36 each), urinary F2-IsoPs were
found to be invariant (2.26±0.9 μg/g creatinine) (Burgos Alves et
al., 2010). In a study of 1647 women (Study of Women's Health
Across the Nation — SWAN) spanning the menopause transition,
mean urinary F2α-IsoP levels in non-smokers did not differ for pre-
and post-menopause: 343±12.4 pg/mL versus 379±19.5 pg/mL
(Sowers et al., 2008). In the SWAN study, 1610 participants (multi-
race/ethnic sample of midlife women) had an overall median concen-
tration of urinary F2α-IsoPs of 433 ng/L, with an overall total range
spanning over an order of magnitude: 167—2074 ng/L (Tomey et al.,
2007). Urinary 15-F2t-IsoP from 16 apparently healthy individuals
ranged from 55 to 348 ng/g creatinine (Haschke et al., 2007).
One study compared 30 subjects with untreated metabolic syn-
drome against 30 age- and gender-matched controls. Mean urinary
F2-IsoPs (pmol/mmol creatinine) were 808 (695–943) versus 664
(590–749), respectively (Tsai et al., 2009). In a study using 11 clinical
urine samples (unspeciﬁed origin), the distribution range for 8-
isoPGF2 was wider and higher than for eight samples from healthy
controls: mean and median of 0.118 and 0.092 ng/mL (range 0.029
to 0.240 ng/mL) for clinical samples versus 0.048 and 0.039 ng/mL
(range 0.017 to 0.084 ng/mL) for controls (Bai et al., 2011). Just for
perspective, of the numerous studies reporting on blood levels, “nor-
mal” concentrations of F2-IsoPs in human plasma were reported as
35±6 pg/mL (0.035 ng/L), versus 1.6±0.6 ng/mL in human urine
(Milne et al., 2007).
Some studies, however, yield rather large ranges. In a study of 246
women, the range for baseline urinary levels of 8-iso-PGF2 was 192–
4873 pg/mg creatinine (Thompson et al., 2005).
A multi-country study used 588 subjects from Sweden (n=220),
Italy (n=203), and Poland (n=165). Modestly higher levels were
found for smokers. Mean levels (and ranges) for urinary F2-IsoPs
(pmol/mmol creatinine) among all subjects were 200 (64–1235)
[n=588]. For individual groups, the levels were: 182 (64–1235)
[n=217] non-smoking males; 213 (70–677) [n=89] smoking
males; 204 (68–449) [n=195] non-smoking females; and 245
(116–752) [n=81] smoking females (Basu et al., 2009).
10.3. Intra- and inter-individual variations in urinary IsoP levels
Studies on temporal variation of urinary IsoP levels have exam-
ined intra- and inter-personal excretion over periods ranging from
days to seasons. Among the ﬁrst studies to examine intra-day vari-
ation in urinary IsoP excretion in healthy subjects were those of
Helmerson and Basu. Urinary 8-iso-PGF2α levels (determined by im-
munoassay) were indistinguishable during a 24-h sampling for each
of 10 healthy subjects, with a mean level of 0.44±0.23 nmol/mmol
creatinine (Helmersson and Basu, 1999). For 13 healthy males and
females, mean urinary 8-iso-PGF2α on 10 consecutive days was
0.27±0.11 nmol/mmol creatinine (Helmersson and Basu, 2001).
Using a method developed speciﬁcally for an 8-iso-prostaglandin
F2α dinor metabolite (2,3-dinor-iPF2α-III), a study of 21 subjects mea-
sured intra- and inter-individual variations in urinary levels (Zhang et
al., 2010). The overall mean was 4.3±0.3 μg/g creatinine. As with
many studies, the mean levels were signiﬁcantly higher for females
than males (5.0±0.6 versus 3.6±0.3 μg/g creatinine). Respective
intra- and inter-individual contributions to total variation were 40%
and 60% (Zhang et al., 2010).
One of the few and most signiﬁcant studies on time-course vari-
ability of urinary IsoPs was a year-long study of 48 randomly selected
middle-aged and elderly Chinese men (Wu et al., 2010). Spot urinary
samples were collected over 4 seasons. Among the markers targeted
were F2-IsoPs and 2,3-dinor-5,6-dihydro-15-F2t-IsoP (15-F2t-IsoP-
M). The mean levels (expressed as the mean interquartile range) for
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inine for F2-IsoPs; the grand mean was 1.90. For 15-F2t-IsoP-M, the
mean interquartile ranges were 0.55, 0.53, 0.51, and 0.52 ng/mg cre-
atinine (grand mean of 0.53). These data reﬂected surprisingly low
variation and high stability among the seasonal levels, especially
given the use of spot instead of 24-h samples.
10.4. Biliary (and fecal) excretion
In examining published data for the levels of a biomarker pro-
jected to be excreted from healthy and diseased individuals, urine is
usually the primary route considered — primarily because of the
ease of sampling urine in clinical studies. But the parallel route of
fecal excretion (via bile and possibly by intestinal excretion [diffusion
into the lumen]) also needs to be examined for BioSCIM. The possibil-
ity of two routes of excretion (urinary and fecal) could also dictate the
need to design different approaches for sewage analysis depending
on whether a portion of the targeted biomarker is not dissolved or
suspended in the aqueous phase or raw sewage, but rather remains
sorbed to the solids. With some biomarkers – coprostanol being one
example (Daughton, 2012) – excretion via the feces can be substan-
tial. For IsoPs, however, few data are available on fecal excretion. It
is also not known whether feces could also harbor IsoPs that are cre-
ated within (but not absorbed from) the gut (as with coprostanol).
In the ﬁrst study of biliary excretion in humans, esteriﬁed F2-
IsoPs were found to be excreted in the bile of healthy individuals
at levels of 188±27 pg/mL. In subjects with bile duct stones and
various diseases of the pancreas, the levels were nearly 3-fold
higher — 523±129 pg/mL and 545±112 pg/mL, respectively (Leo
et al., 1997). Assuming an average daily bile production rate of
600 mL, the total daily elimination of F2-IsoP via the feces for
healthy individuals could amount to roughly 113 ng/day. This
amount may prove to be signiﬁcant compared with urinary excre-
tion — contributing from 23% to 2% of the combined urinary range
reported earlier (500–5000 ng/day); see Section 10: IsoP excretion
data. The only prior study on biliary excretion used rats, where bil-
iary excretion was found to greatly increase upon dosing with car-
bon tetrachloride, and most IsoP was excreted in esteriﬁed form
rather than free (Awad and Morrow, 1995).
11. Differential Stress Index: increasing the sensitivity of BioSCIM
by also measuring biomarkers of health to derive a normalized
index of stress or homeostasis
One of the major challenges facing the use of BioSCIM for asses-
sing community health is the need to accurately know the size of
the contributing population. The population size allows calculation
of per capita contributions to biomarker levels measured in sewage.
Sufﬁciently accurate estimation of population size, however, is
fraught with difﬁculties. One possible approach (ASAP-SCIM: see
Daughton, 2012), which for the ﬁrst time makes use of biomarkers
in sewage, has been published as the prelude to this article, but the
approach still poses a number of challenges for successful veriﬁcation
and implementation; this published paper also discusses the many
limitations to the existing approaches for estimating population
size. Any additional sources of error beyond that involved in biomark-
er analysis and calculation of sewage ﬂow could obscure the ability to
detect otherwise signiﬁcant variations in biomarker levels.
Since the need to calculate community-wide contributions of
biomarkers on a per capita basis is problematic, an alternative ap-
proach would greatly help. One possible approach (referred to
here as the Differential Stress Index) would nullify the need to
know the speciﬁc population size responsible for a measured bio-
marker level. This approach would create a dimensionless ratio by
normalizing the levels of the targeted biomarker of stress (such as
IsoPs) against a second biomarker with orthogonal characteristics.The second biomarker (the denominator) would be selected so
that its excreted levels would move in opposition to the level of
the biomarker of stress (the numerator). To maximize the sensitivi-
ty of the Differential Stress Index, the second marker would ideally
serve as a positive measure of health.
Dimensionless ratios are routinely used in testing for abused
drugs in sports, an example being testosterone/epitestosterone
(Van Renterghem et al., 2010). Another example is a proposed
“index of endogenous anti-inﬂammatory potential”, which uses the
ratio of two oxylipids having opposite effects on inﬂammation
(Gangemi et al., 2005).
Excretion of this second “normalizing” biomarker would have to
meet one of two criteria. Its excreted levels would need to be either:
(1) a constant function of per capita excretion (and therefore serving
as a surrogate measure of per capita population), or (2) a variable
function of a physiological state whose level is an inverse, orthogonal
function of the targeted biomarker.
Two examples of the ﬁrst criterion are creatinine and the fecal ste-
rol coprostanol. Creatinine, although long used in clinical chemistry
for avoiding the problems created by the extent of dilution of urine
(which is problematic for interpreting levels in spot samples), has a
number of problems when applied to sewage (Daughton, 2012). A
more likely candidate is the use of coprostanol as a proxy for popula-
tion size, as proposed by Daughton (2012).
An example of the second criterion is easy to conceptualize but
identifying a real-world candidate from the universe of known bio-
markers proves difﬁcult. The ideal candidate for an inverse, orthogo-
nal biomarker would be one that measures “good health” or “positive
health” — or an array of biomarkers that correlate with the lowest risk
of morbidity and mortality.
Biomarkers are often classiﬁed according to three purposes: mea-
suring dose (exposure), effects, or susceptibility to effect or risk. Sur-
prisingly absent are biomarkers that directly measure or conﬁrm
health or maintenance of homeostasis. The absence of disease is in-
variably used as an indirect surrogate for health; but such a signal is
necessarily one of ever-declining magnitude. With very few excep-
tions, nearly all known biomarkers measure some attribute of disease
or stress. The few possibilities of positive markers of health (which in-
crease in magnitude) tend to not meet one or more of the three major
criteria for use with BioSCIM (Table 1). In particular, they must be:
(1) sufﬁciently stable to be extensively excreted – preferably into
urine (or possibly feces) – and persist in sewage, (2) excreted in the
absence of stress at levels with low intra- and inter-individual daily
basal variation (including not being inﬂuenced by normal dietary
changes), (3) immune to confounding — introduced into sewage pre-
dominantly as a result of endogenous human metabolism (with min-
imal exogenous contribution, such as by raw or cooked foods), and
(4) have a chemical structure amenable to detection in the complex
matrix of sewage.
A biomarker of health would provide an independent variable
against which to normalize the levels of the biomarker targeted for
measuring disease or stress. The per capita contributions of the two
biomarkers (from opposite ends of the health-disease continuum)
in sewage would vary in opposing directions. Normalizing a measure
of negative health against a measure of positive health (creating a di-
mensionless index) would not just eliminate the need to know the
population size, it would also serve to greatly amplify the signal
that would otherwise be provided solely by measuring a biomarker
of stress (as a result of the numerator and denominator being in-
versely related).
11.1. Biomarkers of health — anti-inﬂammatory eicosanoids
A clear example of one of the few documented biomarkers of pos-
itive health would be one of the many eicosanoids that serve as
counter-regulators to the inﬂammatory oxylipids. The chemistry
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complex and intricately inter-connected. They are also incompletely
understood, with new knowledge continually emerging. The
counter-regulators of inﬂammation are involved not just with
down-regulating inﬂammation, but also with “resolving” (or repair-
ing) inﬂammatory damage (catabasis). This group of anti-
inﬂammatory, pro-resolving eicosanoids comprises the specialized
classes of proactive, lipid mediators known as lipoxins, resolvins, pro-
tectins, and maresins, many of which are biosynthesized from the
omega-3 essential fatty acids eicosapentaenoic acid (EPA) or docosa-
hexaenoic acid (DHA). Even though these anti-inﬂammatory pro-
resolution eicosanoids are produced at highest levels during the re-
covery phase (resolution) of chronic disease, their presence reﬂects
a healthy immune system; their levels are notably suppressed in
those who are unable to resolve chronic inﬂammation. Overviews
are available (Das, 2010; Levy, 2010; Maderna and Godson, 2009;
Serhan and Petasis, 2011).
These pro-resolving, hydroxylated, polyunsaturated fatty acids are
produced in localized areas of tissues at extremely low concentrations
(pM–nM), reﬂecting their hormonal-like potency. These oxylipids
would make ideal biomarkers of health. But unfortunately, little is
known about their excretion in urine, and their low levels might chal-
lenge analysis. Limited data, however, indicate that certain drugs
(e.g., COX-2 and LOX inhibitors) might inhibit the resolution process,
whereas others might allow it (e.g., aspirin, statins, and glucocorti-
coids) (Serhan and Petasis, 2011).
One of the only studies published to date on the urinary excretion
of pro-resolving mediators involves a lipoxin, LXA4. Its urinary levels
were roughly 2 orders of magnitude lower than those commonly
reported for IsoPs — roughly 0.02 ng/mg creatinine (Gangemi et al.,
2005). The only published method for lipoxins in urine is an immuno-
assay, and it is unknown whether its sensitivity and speciﬁcity would
sufﬁce for sewage.
11.2. Other potential markers of positive health for use as denominators
in the Differential Stress Index
In addition to the pro-resolver oxylipids, several other potential
biomarkers of “positive health” exist but for a variety of reasons
would not work as the denominator in a differential stress index.
The production of some biomarkers reﬂects dual actions — serving
as indicators of both positive health attributes and negative aspects
of disease. Two sometimes paradoxical outcomes can come about
from the same mode of action — sometimes as a function of the con-
centration or other times as a function of site or timing of production.
One example is the production of an array of halogenated lipids from
the oxidative stress created by endogenous hypohalous acids. This
can result, for example, from collateral damage from immune re-
sponse in ﬁghting an infection (e.g., Spickett, 2007).
11.2.1. F3-isoprostanes
While the major focus of IsoP research has been on the F2-series,
many other IsoPs can be formed from various polyunsaturated fatty
acids other than arachidonate. In 1997, the IsoP F3-series was
reported to form from the non-enzymatic free-radical peroxidation
of eicosapentaenoic acid (EPA), an essential omega-3 fatty acid
whose primarily dietary source is ﬁsh oil (Nourooz-Zadeh et al.,
1997); additional amounts of F3-IsoP could also be contributed by
beta-oxidation of F4-IsoP generated by analogous peroxidation of
the related omega-3 docosahexaenoic acid (DHA). The in vivo forma-
tion of F3-IsoP was ﬁrst shown by Gao et al. (2006).
Of the six possible series of F3-IsoPs (5-, 8-, 11-, 12-, 15-, and
18-series), the most prevalent in urine seem to be 5-epi-8,12-iso-
iPF3-VI and 8,12-iso-iPF3-VI, whose ratio is relatively ﬁxed (Song
et al., 2009).F3-IsoPs tend to be produced more efﬁciently than F2-IsoPs —
probably being more easily formed thermodynamically since EPA
and DHA (having 5 double bonds) are more unsaturated than arachi-
donic acid (AA) and therefore are more readily oxidized. When EPA
and DHA are present, they might therefore serve to competitively re-
duce the oxidation of AA, resulting in lower production of inﬂamma-
tory F2-IsoPs. Indeed, clinical data show that EPA and DHA can reduce
F2-IsoP levels (Mas et al., 2010b).
Evidence also indicates that the F3-IsoPs possess their own anti-
inﬂammatory actions (Roberts and Milne, 2009). Although the
generation of F3-IsoP from EPA is much more efﬁcient than F2-IsoP
from AA, urinary levels of F2 are substantially higher than F3, probably
because of the much higher levels of AA than EPA (or DHA), whose
dietary source is limited primarily to ﬁsh oil. Moreover, the intra-
individual excretion rates of F3-IsoPs seem to be much more variable
than for F2-IsoPs. Nonetheless, F3-levels, if detectable in sewage,
might have potential as orthogonal biomarkers against which to
normalize F2 levels.
Other factors can disqualify a biomarker from use with BioSCIM.
Some of these are illustrated by the adrenal androgen dehydroepian-
drosterone (DHEA), which is one of the few biomarkers tracked in
existing clinical tests that purportedly reﬂects positive health (see
the Supplementary materials section “Aspects of biomarkers not suit-
able for BioSCIM”).
12. Consideration of other biomarkers for SCIM
Other biomarkers were considered for use in an initial (proof of
principle) BioSCIM application but were determined to have one or
more negative attributes compared with IsoPs; many of these also
have extensive histories of use in clinical research, such as prostate
speciﬁc antigen (PSA) and various hormones. Among these are not
just other markers of lipid oxidation [nitrated fatty acids; plasmalo-
gens (Leßig and Fuchs, 2009), halohydrins (Spalteholz et al., 2004),
and other chlorinated lipids (Spickett, 2007)], but also products of
protein oxidation [o,o′-dityrosine, nitro-tyrosine, and halo-tyrosines
(Mohiuddin et al., 2006)], DNA (oxidized guanine derivatives such
as 8-oxoguanine) (Andreoli et al., 2011; Winnik and Kitchin, 2008),
and uric acid (metabolized to allantoin) (Il'yasova et al., 2010); for
an overview, see Jain (2010). Many of the halogenated biomarkers
are formed from the action of myeloperoxidase (MPO), which
uniquely generates hypohalous acids from halides at physiological
concentrations (Klebanoff, 2005).
While it might seem that halogenated products could serve to fa-
cilitate detection in sewage, the ubiquitous occurrence of myriad
organohalogen natural products, particularly in marine life, might
confound the use of a halogenated biomarker for SCIM. The occur-
rence of organohalogens in food sources might serve as a signiﬁcant
exogenous source (Gribble, 2010).
13. Biomarker proﬁles and community-wide allostasis
The utility of BioSCIM could be enhanced with the incorporation of
a select array of biomarkers — preferably reﬂecting a wide spectrum
of biological regulatory processes and providing complementary, or-
thogonal measures of disease (or health). It is now widely recognized
that aggregate exposure to multiple stressors sharing the samemech-
anism or mode of action – but at individual levels below any known
effects levels – can yield adverse effects as a result of their combined
contributions. But much less is known with regard to stressors acting
by unrelated pathways and yielding unrelated effects (mixed-out-
come effects). The question is whether individual effects, which
would otherwise not prove adverse in isolation from others, when
combined with the unrelated effects elicited by orthogonal-acting
stressors, might serve to exceed the allostatic load.
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effects from combined cumulative exposures. Such a composite pic-
ture – or proﬁle – would more closely align the BioSCIM concept
with the biological passport approach used in sports random drug
testing (referenced earlier). Perhaps the ﬁrst and most comprehen-
sive attempt at designing a composite measure of how the body re-
sponds to cumulative exposure to all stressors is the concept of
allostasis and its quantitative measure referred to as allostatic load
(McEwen and Stellar, 1993).
In practice, allostasis is measured by the combined levels of
roughly a dozen or more biomarkers whose increasing (or decreas-
ing) levels are associated with an increased risk of mortality. Con-
ceptually, allostasis reﬂects the body's overall status in maintaining
homeostasis and indicates when perturbations exceed that capacity.
The allostatic load accounts for the two forms of stress: quotidian
(ordinary, recurring, persistent, chronic, episodic, daily stress,
which tends to be perceived as minor), and infrequent, intense,
acute forms of stress. Signiﬁcantly, allostasis would also account
for health disparities caused by stress resulting from origins usually
not reﬂected by traditional chemical-exposure monitoring —
stressors such as socioeconomic status, ethnicity, race, and psycho-
logical stress (Djuric et al., 2008).
A recent review on allostasis is available from Juster et al. (2010),
and a study examining the weaknesses of the allostatic load concept
is presented by Dowd et al. (2009). A variety of analogous approaches
intended for practical clinical application have been proposed (Ochi
and Cutler, 2003; Southern, 2010; Veglia et al., 2010).
14. Potential role for BioSCIM in revealing health disparities
(via IsoPs)
Health disparities reﬂect the disproportionate morbidity, mortali-
ty, stress, and degraded productivity and sense of well being experi-
enced as a result of differential exposure by racial and ethnic
minorities and by the disadvantaged/under-served, such as rural
and poor populations. These factors coalescence into greater need
for healthcare but which is often not available. Health disparities
often result from combined actions of genetic and epigenetic factors,
social setting, psychological stress (and impact on well-being), envi-
ronmental stressors (including diet), lifestyle choices, and insufﬁcient
access to medical care (Djuric et al., 2008). Traditionally, an over-
wrought focus has been devoted to chemical pollutants at the exclu-
sion of numerous other stressors (Morello-Frosch et al., 2011) —
many of which have outcomes measurable by oxidative stress.
The need to assess cumulative impacts of aggregate stressors at
the community level is certainly an emerging interest and need. To
date, the approach used in assessing cumulative impacts focuses on
assessing proximity to known hazards, social vulnerability indicators,
land use, demographics, and other signs or measures of possible dis-
proportionate exposures. The variety of methodologies employed
have been summarized (Alexeeff et al., 2010; Jakubowski and
Frumkin, 2010; Medina-Vera et al., 2010; Zartarian and Schultz,
2010). Some of the many projects underway have been summarized
(SEHN/CHE, 2011). BioSCIM could help as a new tool in assessing cu-
mulative exposure and risk in communities, such as with EPA's
Community-Focused Exposure and Risk Screening Tool (C-FERST)
(Zartarian et al., 2011).
These methodologies are not quantitative, but rather designed to
facilitate relative rankings of communities (e.g., from disproportion-
ate exposure to one or more documented stressors). While conven-
tional measures of stress or disease are used (e.g., known incidence
of disease such as cancer), none of the approaches relies on bio-
markers of exposure or effect.
An emerging appreciation for health disparities and environmen-
tal justice led to the creation of what is now the National Institute
on Minority Health and Health Disparities (NIMHD). Needed arequick and inexpensive measures that account for the multi-factorial
nature of health disparities — including those of psychosocial origin
(e.g., emotional stress, such as brought about by socioeconomic sta-
tus). A biomarker or suite of biomarkers that reﬂects cumulative
stress from all sources would be extremely useful. It appears that no
research has ever been published on determining cumulative expo-
sures to any class of stressor via biomarkers; a major impediment
has been the lack of an approach for collecting samples on a
community-wide scale (Lewis et al., 2011). Sexton and Linder discuss
the complexities of assessing cumulative risk and the additional chal-
lenges posed by non-chemical stressors — in particular psychosocial
stress (Sexton and Linder, 2011).
With the appropriate biomarker(s), BioSCIM holds potential for
helping to reveal hidden or emerging disparities, and to assess the ef-
fects of attempted interventions. It could help accelerate and improve
our understanding of community-wide health disparities. Conven-
tional monitoring of biomarkers in individuals requires considerable
resources, and major challenges and limitations are posed by ﬁeld
work (especially in rural areas), all adding to delay in dissemination
of data. Conventional health disparities research can suffer from:
bias introduced by selection of a limited study population, by accessi-
bility of clinics or in-home clinicians, or by sample processing, stor-
age, and shipping (Djuric et al., 2008).
In an overview of biomarkers (Djuric et al., 2008), a range of bio-
markers was examined for assessing health disparities. In the data ex-
amined for the work reported here, only IsoPs were deemed suitable
for use in BioSCIM because of shortcomings with one or more of the
criteria in Table 1. For example, although baseline plasma levels of
15-F2t-IsoP were reported to not differ between African Americans
and white Americans, levels of 15-F2t-IsoP increased more in African
Americans in response to acute hyperlipidemia, which is a simulation
for postprandial oxidative stress and which may be a factor in ethnic
differences in cardiovascular and renal risk (Lopes et al., 2003). In a
study of cognitive aging, Caucasians were reported to have lower
levels of urinary IsoPs than Hispanics (Insel et al., 2011).
15. Limitations of BioSCIM
A wide array of potential problems could limit the application of
BioSCIM, regardless of the targeted biomarker. Foremost among
these are problems with the sampling of sewage streams representa-
tive of the entire population served by the STP. This aspect has been
discussed (Daughton, 2012). The sewage inﬂuent stream to an STP
at any point in time serves as a sampling of combined excretion
from a random sub-population of the total population served by the
STP. The relative size of this random sub-population is also unknown.
This necessitates the use of continuous in-stream sampling designed
to collect the total ﬂux of the biomarker over a sufﬁciently long
time (probably at least a day). This poses a number of challenges
with respect to the technologies used in sampling. Moreover, howev-
er, despite the sophistication of whatever sampling approach might
be used, additional hurdles are faced with respect to the representa-
tiveness of the data. These result from the fact that diurnal variations
in the excretion of urine and fecal matter, coupled with possible diur-
nal variations in biomarker excretion, cannot be fully represented in
any continuous sampling process simply because a certain portion
of the population served by the STP will be absent from the service
area at any point in time.
Several additional limitations include factors having the potential
for confounding BioSCIM data based on IsoP measurement. These
variables range from those with the potential to alter IsoP formation
and excretion (in the absence of exposure to a stressor) to those
that create analytical artefact. Major variables include age, medica-
tions and food supplements, dieting (e.g., fasting), nutrition, sewage
contributions from healthcare facilities (such as long-term care facil-
ities and hospitals, where excreted levels could be expected to be
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would inﬂate the levels resulting from endogenous stress. Correc-
tions could be implemented for some of these; an example would
be the age structure of the local population, where perhaps demo-
graphics could be used to account for age. Several examples of con-
founding factors are provided in Table 3; these are discussed in
more detail in the Supplementary materials (see section on “Poten-
tial Confounders”).
16. The future
Even though a BioSCIM application remains to be reduced to prac-
tice (whether based on IsoPs or alternative biomarkers of stress or
health), foreseeable advancements in various technologies could
clearly add further power to the approach. These could range from
the mundane and obvious to the esoteric. Most simply, better bio-
markers of oxidative stress might well exist (e.g., those with greater
excretion rates or more easily analyzed) but perhaps have simply
not yet been recognized. The development of a certiﬁed reference
material (e.g., IsoPs in a matrix simulating urine or sewage) could
help eliminate a large portion of the uncertainty deriving from analyt-
ical measurements between labs (especially when using differing
methodologies and instrumentation).
More advanced developments include development of in-line, auto-
mated sewage monitoring capability. With the development of in-
stream biomarker sensors that could function in raw, untreated sewage,
data could be streamed from sewage distribution lines to web-based
community dashboards displaying continuous real-time information
showing absolute status or trends. The data generated by BioSCIM
could be validated by using the voluminous health data being made
available via the Community Health Data Initiative (CHDI), launched
in 2010 by the US Department of Health & Human Services (HHS,
2010). These capabilities could eventually also provide the type of in-
stant feedback that has proved so effective in motivating individuals
to begin changing their behaviors in ways conducive to achieving con-
tinual improvements in health or well-being. For example, the use ofTable 3
Factors with potential to confound IsoP levels for use in BioSCIM.a
Confounding factor Examples
Raw and cooked foods as possible
exogenous source of IsoPs
Lipid oxidation during frying (e.g., foods high in
polyunsaturated fatty acids); however,
calculations show that this source could be a
minor contributor to IsoP levels in sewage
(compared with levels originating from
endogenous metabolism). IsoPs seem to occur
only at low levels in raw foods.
Dietary lipid inﬂuence on
IsoP production
Dietary omega-3 fatty acids (e.g., EPA and DHA)
can lead to reductions in IsoP formation (pos-
sibly by competing with arachidonic acid dur-
ing oxidative stress); in this sense, omega-3
fatty acids could be viewed as factors protective
of oxidative stress. Certain unsaturated fatty
acids, however, can inhibit the metabolism of
IsoP, leading to enhanced levels.
Exogenous antioxidants as
inhibitors of IsoP production
Antioxidants in foods and in nutritional
supplements can be viewed either as potential
confounding factors or as a reﬂection of a
behavior that can improve health. Studies of the
inﬂuence of antioxidants on reducing IsoP
levels are often inconsistent and sometimes
contradictory. Dosage and overall baseline
health status are determinants in outcomes.
Other dietary inﬂuences on IsoPs Caloric restriction increases IsoP excretion in
obese subjects. Hyperglycemia can increase
IsoP levels several fold.
a See Supplementary materials for detailed examples and discussion, along with
supporting references.feedback and peer-to-peer comparisons (such as via social networking
sites) has been shown effective in reducing household energy usage
(Foster et al., 2010). BioSCIM data revealing a clear time trend for a
given STP could be used as positive reenforcement for communities
possessing healthy lifestyles, or as a means to ﬂag those communities
where certain factors may be degrading health; an ability to predict
declining community health allows for development of interventions.
The availability of inexpensive sensors that could target IsoPs
and other biomarkers would clearly advance the implementation
of BioSCIM. Recent advances in sensor technology are bringing this
closer to reality. One example is the adoption and reengineering of
the ubiquitous personal glucose monitor (used by diabetics) for
the detection and quantitation of a broad array of new analytes
via the use of functional-DNA conjugated to invertase (which hydro-
lyzes sucrose to yield glucose) (Xiang and Lu, 2011). Inexpensive
monitors could empower local communities to participate in the
implementation of BioSCIM.
A more esoteric future possibility would be the development of
what might be called “health checks” for entire communities. One ap-
proach would be the use of an exogenous chemical probe specially
designed to reﬂect the level of active stress when taken orally — for
example, by way of producing unique metabolites when subject to
peroxidation. If a sufﬁcient portion of a community's population par-
ticipated, then sewage could simply be analyzed for a metabolite
unique to a chemical probe and which is indicative of oxidative stress.
Indeed, such chemical probes have been proposed for use in clinical
medicine (Khatib et al., 2007; Szuchman et al., 2008; Vaya, 2008;
Vaya and Tamir, 2008).
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